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Summary 
 
 
I spent my PhD fellowship in Prof. Graziani’s Lab, at the Department of Translational Medicine in 
Novara with the supervision of Prof. Filigheddu. 
During the three years of my PhD program I contributed to the discovery that ghrelin peptides 
activate anti-atrophic signaling by acting directly in the skeletal muscle, thus protecting from 
muscle wasting both in vitro and in vivo. In addition, we showed that such anti-atrophic activity is 
mediated by the binding to a novel yet unidentified receptor, herein referred as “GhrlR2”, 
providing the first genetic evidence for a novel ghrelin receptor. These findings have been 
published in the Journal of Clinical Investigation in 2013 (Porporato, 2013). We also showed that 
the mechanisms underlying ghrelin anti-atrophic activity do not overlap with the IGF-1 pathway, 
the best characterized anabolic factor in skeletal muscle. Differently from IGF-1, AG and UnAG 
inhibit only protein degradation, without stimulating protein synthesis and hypertrophy. Although 
the identity of the novel receptor is still missing, the data presented here demonstrate that the 
GhrlR2 is bona fide a Gs-coupled receptor. Finally, we investigated the role of UnAG in 
counteracting cancer cachexia. The finding that ghrelin protects cancer-associated muscle wasting 
far more weakly than denervation- and fasting-induced atrophy, suggesting that cachectic muscle 
may acquire a condition of ghrelin resistance. Indeed, we showed that pro-cachectic cytokines, 
TNF and IFN, induce ghrelin resistance in muscle cell in vitro, by inducing p101 regulatory 
subunit of PI3K, an enzyme known to promote Gs-coupled receptors downregulation. Overall, 
these findings may have important translational implications in pathologies involving 
inflammation-associated muscle wasting such as cachexia, muscle dystrophies, and aging-
associated sarcopenia.  
 
  4   
Introduction 
 
 
Regulation of skeletal muscle mass 
Cell size is the result of a balance between protein breakdown and protein synthesis. In the 
skeletal muscle, when the first exceeds the protein synthesis, there is the onset of atrophy, 
whereas in the opposite condition skeletal muscle grows or becomes hypertrophic [1]. Recent 
findings have highlighted multiple levels of connections between catabolic pathways, mainly the 
ubiquitin-proteasome system and the autophagy-lysosome pathway, and biosynthetic pathways.  
Skeletal muscle grows in the postnatal period, and increases its mass becoming hypertrophic in 
adults, for example in response to mechanical overload, through two main signaling pathways 
triggered by: the positive regulator insulin-like growth factor (IGF-1), and the negative regulator 
myostatin [2].  
 IGF-1 is the best characterized hypertrophic factor in skeletal muscle (Fig. 1, from [3]). It 
binds to IGF1R inducing phosphorylation of insulin receptors substrate 1 (IRS1), that is a 
highly regulated component for the majority of IGF-1 activities [4]. Indeed, several E3 
ubiquitin ligases control IRS1 under different conditions [4]: for example, SOCS1 and SOCS3 
elicit insulin resistance induced by inflammation through ubiquitination of IRS1 and IRS2 
[5], and Fbox40-SCF complex degrades  IRS1 soon after IGF-1 stimulation, limiting the 
activation of the downstream pathway [6]. IGF-1 activates both mitogen-activated protein 
kinase/extracellular signal-regulated kinase (MAPK/ERK) and the phosphoinositide 3-kinase 
(PI3K)/Akt pathways. It has been demonstrated that the major hypertrophic signal comes 
from PI3K/Akt pathway, and that, conversely, ERK pathway is negligible [7]. The IGF-1-
triggered Akt inhibits GSK3and activates mTOR signaling to induce protein synthesis [8-
10]. The serine/threonine kinase mTOR is regulated by multiple factors, including amino 
acids, AMPK, phosphatidic acid, and Akt, and forms two multiprotein complex, mTORC1 
and mTORC2, characterized by the two key components raptor and rictor, respectively 
[11]. Protein synthesis is mainly attributable to mTORC1 activation, while mTORC2 blunts 
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protein degradation [11, 12]. Indeed, genetic studies revealed that mice without raptor in 
the skeletal muscle show a reduced postnatal growth, but mice lacking rictor had not 
abnormalities [13]. Consistently, treatment with rapamycin, that inhibits mTORC1 and, in 
chronic treatment, impairs also mTORC2 activity,  blunts skeletal muscle growth, 
regeneration, and compensatory hypertrophy [14-16].  
 
 
           Figure 1: The IGF-1 pathway regulating skeletal muscle mass [3] 
 
 
 Conversely to IGF-1, myostatin reduces skeletal muscle mass. Myostatin is a member of 
TGF family, and induces atrophy both in vitro and in vivo [17, 18], by activating Smad2 and 
Smad3 transcription factors [19]. It is likely that myostatin, similar to Activin A, another 
member of TGF family, deregulates Akt/mTOR pathway [19-21], enforcing its ability to 
induce muscle wasting.  
 
Among the other factors involved in skeletal muscle growth and hypertrophy, such as serum 
response factor (SRF), androgens, PGC-14, and nNOS [2], -adrenergic receptors (-ARs) 
(Navegantes, 2002; Lynch, 2008) [22, 23], in particular 2-AR agonists, and Wnt7a/Fzd7 play a 
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crucial role in the regulation of skeletal muscle mass [22-27]. Both 2-ARs and Wnt7a/Fzd7 trigger, 
besides Akt pathway, cAMP signaling, pointing out the crucial role of this second messenger in the 
regulation of skeletal muscle mass [28]. Indeed, at least four receptors coupled to Gs induce 
skeletal muscle hypertrophy: Fzd7, 2-AR, CRFR2, and LPAR (Fig. 2, from [28]). It has been also 
demonstrated that cAMP affects not only differentiated myofibers, but also finely regulates 
myogenesis [28]. Surprisingly, it has been recently reported that the expression of Gi2 is sufficient 
to induce muscle hypertrophy and regeneration [29], however, it seems that the modulation of 
cAMP production in skeletal muscle is not the primary role of Gi2, which mainly acts through 
phospholipase C and protein kinase C [28]. 
 
 
Figure 2: G protein-coupled receptors (GPCRs) inducing skeletal muscle hypertrophy [28] 
 
 
Conversely, when protein degradation exceeds protein synthesis skeletal muscle loses its mass 
becoming atrophic. Skeletal muscle wasting is induced by several stimuli: loss of muscle mass may 
occurs locally, in response to denervation or inactivity, but also as a systemic response during 
fasting or different diseases, such as cardiac and renal failure, excessive glucocorticoids, AIDS, 
sepsis, trauma, and cachexia [30]. It is worth noting that the modulation of skeletal muscle mass 
not always follow the simple rule in which hypertrophy occurs when protein synthesis increases 
and protein degradation decreases, and conversely for muscle atrophy [2]. Indeed, it has been 
reported, among others, that muscle denervation is characterized by an increase in both protein 
synthesis and degradation [2]. However, it is undoubted that skeletal muscle atrophy shows an 
accelerated proteolysis of both myofibrillar and soluble proteins, leading to the loss of muscle 
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mass, leading to reduced body weight, fatigue, weakness and increased disability [30]. Specifically, 
the accelerated proteolysis derives from two highly conserved pathways: the ubiquitin-
proteasome system (UPS) and autophagy [30, 31]. Both these pathways in skeletal muscle are 
constitutively active in physiological condition, but in pathological states there is an increase of 
their activity [32-39].  
Skeletal muscle atrophy is an active process that is managed by a definite transcriptional program. 
Through microarray analysis it has been discovered a pool of genes regulated in different atrophic 
conditions, called atrogenes [33-36]. Globally, it has been identified 120 atrophy-related genes, 
including those related to UPS and autophagy, and, among these, Atrogin-1/MAFbX and MuRF1, 
two muscle specific E3-ubiquitin ligases, are the most induced genes in several atrophic states [33-
35, 40], and are the principal proteins involved in the UPS. Atrogin-1 and MuRF1 are both 
dispensable for skeletal muscle growth, but their ablation reduces denervation-, starvation-, and 
glucocorticoid-induced atrophy [40, 41]. The PI3K/Akt/mTOR pathway discussed above, although 
in dividing cells regulates proliferation, in non-dividing cells, such as muscle cells, is the major 
regulator of skeletal muscle mass not only stimulating protein synthesis, but also inhibiting protein 
degradation [3]. Indeed, mTOR inhibits both UPS and autophagy [42-44], and Akt phosphorylates 
the transcription factors belong the family of forkhaed box protein O (FoxO), impairing their ability 
to translocate into the nucleus and induce atrogenes program [30]. Among these, FoxO1 and 
FoxO3  are likely activated in all types of skeletal muscle wasting [30], and FoxO3 alone is sufficient 
to induce skeletal muscle atrophy upregulating UPS and autophagy [38, 39, 45]. Beyond FoxO 
transcription factors, other crucial regulators of atrogenes expression are NF-kB, activated by 
cytokines, SMAD2 and SMAD3, triggered by myostatin, and glucocorticoid receptors [30]. 
Interestingly, although Atrogin-1 and MuRF1 are the best characterized E3 ubiquitin ligases, it has 
been demonstrated that also others ubiquitin ligases are involved in skeletal muscle, such as 
E3alpha-II, activated upon tumor necrosis factor a (TNF) and interleukin-6 (IL-6) treatment [46], 
Mul1, inducing mitophagy during muscle wasting [47], and Musa1, inhibited by bone 
morphogenetic protein to induce muscle hypertrophy [48]. 
In conclusion, skeletal muscle mass is finely regulated by several different pathways, that own 
multiple cross-talks and feedback regulations, and the upregulation of a particular signaling leads 
to a net increase or decrease in muscle mass (Fig. 3, from [30]). 
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Figure 3: Signaling pathways leading to skeletal muscle atrophy [30] 
 
 
Cancer cachexia 
 The term “cachexia” derives etymologically from the Greek kakos and hexis, meaning “bad 
condition”. It is a multifactorial syndrome associated with several diseases, such as cancer, heart 
and renal failure, AIDS, and rheumatoid arthritis [49]. Development of cachexia reflects poor 
prognosis, and, despite the heterogeneity of the pathological causes of cachexia, there are two 
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major common factors: weight loss and inflammation [50]. Consistently, the only drugs currently 
utilized to counteract cachexia are glucocorticoids, to inhibit inflammation, and megestrol acetate, 
to stimulate appetite, although both become ineffective in the long term [50].  
It has been reported that 30-80% of cancer patients develop cachexia, depending on tumor type, 
and in the 15% of cases the body weight loss is extremely severe, exceeding the 10% of initial body 
weight [51]. Cancer cachexia is characterized by a strong reduction of quality of life, related mainly 
to symptoms such as fatigue, weakness, asthenia, anaemia, anorexia, and psychosocial distress 
[50, 51], and leads to more than 20% of all cancer deaths via respiratory failure, cardiac failure, 
and metabolic derangement [49]. Despite several definitions of cancer cachexia, it has been 
recently achieved a consensus [52]: “Cancer cachexia is defined as a multifactorial syndrome 
characterized by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that 
cannot be fully reversed by conventional nutritional support and leads to progressive functional 
impairment. The pathophysiology is characterized by a negative protein and energy balance driven 
by a variable combination of reduced food intake and abnormal metabolism”. Clinically, 
progression of cachexia may be classified into three different stages, although not all cancer 
patients follow the entire process: precachexia, cachexia, and refractory cachexia [52]. Patients in 
the last stage, associated with very advanced or rapidly progressive cancer, show low performance 
status and a life expectancy of less than 3 months, without any possibility to manage weight loss 
[52].  
It has been proposed that cancer cachexia may be considered as a state of “autocannibalism”, in 
which tumor orchestrates a host response to obtain fuel for its growth, such as glucose, amino 
acids, and free fatty acids (Fig. 4, from [50]), or a generic host response to stress and injury leading 
to a “double-edged sword” [53]. Interestingly, tumors with the same origins and similar growth 
patterns may present or not cachexia [53], suggesting that little differences in genetic background 
strongly influence cachexia development. For example, cachexia prevalence in pancreatic and 
gastric cancer has been associated with single-nucleotide polymorphisms in the genes encoding IL-
6, IL-1 and IL-10 [53]. Finally, also treatments such as surgery, chemotherapy, and radiotherapy 
contribute to cachexia, making cancer cachexia an extremely complex syndrome to understand 
and to counteract.  
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Figure 4: Metabolic response to tumor in cancer cachexia [50] 
 
 
Tumor affects the functions of skeletal muscle, brain, liver, heart, gut, and adipose tissue, leading 
to the definition of cancer cachexia as a multi-organ syndrome (Fig. 5, from [50]). However, the 
critical issue is the loss of skeletal muscle mass, which contributes to more than 40% of body 
weight [50]. Hence, the main goal of current investigations are to counteract skeletal muscle 
wasting during cachexia.  
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Figure 5: Multi-organ affection in cancer cachexia [50] 
 
 
In cancer cachexia skeletal muscle is affected by multiple mechanisms. Indeed, the severe wasting 
is the result of an unbalance between anabolic and catabolic signaling, mainly due by a reduction a 
IGF-1/Akt signaling and by an up-regulation of UPS, although also autophagy plays a crucial role 
[54]. Moreover, in cancer cachexia there is a loss of dystrophin and nNOS, a dystrophin-associated 
complex member, destroying the membrane integrity, and thus inducing atrogenes activity [55, 
56]. Interestingly, it has been reported that cancer cachexia is associated also with an impairment 
skeletal muscle regeneration [57-61]. In particular, cachectic serum induces a NF-kB-mediated 
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overexpression of myogenic Pax7 transcription factor [61], leading to a block of the differentiation 
process, as previously reported [62].  
Skeletal muscle is affected by the tumor both directly, releasing pro-inflammatory cytokines and 
cachectic factors, and indirectly, inducing chronic inflammation and multi-organ response that 
leads to anorexia, hormonal deregulation, acute phase response, autonomic nervous system 
deregulation, and insulin resistance [51, 53]. Among the cachectic factors released by tumor, zinc-
2-glycoprotein (ZAG) and proteolysis-inducing factor (PIF) are the best characterized [51]:  
 ZAG, or lipid mobilizing factor (LMF), induces lipolysis both directly, through cAMP-
mediated activation of hormone-sensitive lipase (HSL), and indirectly, increasing the white 
adipose tissue (WAT) response to catecholamine [51, 63]. Moreover, LMF enhances lipid 
oxidation, likely through 3-AR-mediated increase in the expression of uncoupling protein 
1 (UCP1) [51]. The UCPs dissipate mitochondrial proton gradient, thus decreasing ATP 
synthesis,  and, among the three isoforms, UCP1 is expressed only in the brown adipose 
tissue (BAT), UCP2 is present in several tissues, and UCP3 is produced in BAT, heart, and 
skeletal muscle [64]. Besides UCP1, LMF/ZAG increases the expression of both UCP2, in 
skeletal muscle and tumor cells, and UCP3, in skeletal muscle [51]. Notably, it has been 
reported that LMF is detectable in serum cancer patients proportionally to weight loss 
extent [65]. Interestingly, LFM/ZAG, acting through -ARs, stimulates protein synthesis and 
inhibits protein degradation in murine myotubes [66], that could account for the initial loss 
of fat, instead of skeletal muscle mass, in some cancer patients [63].  
 
 PIF is a sulfated glycoprotein, that has been found excreted in urine proportionally to the 
extent of weight loss in cancer patients [51]. The intravenously injection of PIF in mice 
induces a severe and rapid loss of lean body mass, affecting neither food nor water intake 
[67, 68]. Consistently, PIF decreases protein synthesis and triggers protein degradation, 
increasing the expression of components of UPS, through NF-kB activation. The receptor 
activated by PIF has been found in skeletal muscle and in liver, but not in adipose tissue 
[69]. Importantly, PIF induces NF-kB- and STAT3-mediated expression of cytokines acting 
directly in the liver [70, 71], contributing to elevation of pro-inflammatory cytokines in 
cancer cachexia.   
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Besides ZAG and PIF, it has been recently demonstrated that tumor release parathyroid-hormone-
related protein (PTHrP), which induces adipose tissue browning enhancing thermogenesis and 
energy dissipation [72]. The block of PTHrP with specific antibodies impairs adipose tissue 
browning and, importantly, skeletal muscle wasting [72]. However, authors claimed that PTHrP 
does not act alone in the induction of skeletal muscle wasting, suggesting the involvement of 
others tumor factors [72]. Indeed, besides PIF, tumor produces pro-inflammatory cytokines, such 
as TNF, IL-6, IL-1, and interferon gamma (IFN), that, together with cytokines released by the 
host, play a crucial role in the development of cachexia, although the dissection of the activities of 
each cytokine may be extremely difficult, due to the high redundancy between their activities. 
 TNF, or cachectin, inhibits differentiation of both adipocytes and skeletal myoblasts, and 
induces cachexia in mice [73-76]. In C2C12 myotubes, TNF affects both canonical and 
alternative NF-kB pathways, chemokines network, Notch1 signaling, and proteasome 
pathway [77]. Specifically, TNF triggers skeletal muscle atrophy, enhancing protein 
degradation [78-81], through ROS production and NF-kB-mediated increase of UPS 
components [82, 83]. Moreover, TNF-activated NF-kB leads to MyoD downregulation, 
inhibiting myogenesis [74]. Moreover, TNF induces insulin resistance in skeletal muscle 
through p38 activation [84]. In adipocytes, TNF stimulates lipolysis likely through the 
MAPK- and NF-kB-mediated downregulation of PLIN, which is a barrier to lipolysis [85, 86]. 
However, in cancer patients the correlation between circulating TNF levels and weight 
loss is questionable. Indeed, many studies failed to observe skeletal muscle wasting 
induced by TNF, due to its several systemic effects, such as shock, anemia, and release of 
other pro-inflammatory cytokines [30]. It is possible that serum TNF correlates better 
with the disease stage, reflecting tumor size, than with weight loss [51]. However, the 
relevance of TNF in cancer patients is currently under investigation. Indeed, the inhibition 
of TNF showed no benefit in patients [30]. It is possible that TNF acts as a facilitator but 
it needs to synergize with other cachectic factors to induce atrophy, or that TNF accounts 
only a subset of tumor types [53]. Indeed, TNF activity on muscle cells in vitro depends on 
concentration and treatment duration [87-89].  
 
 IL-6 levels, in contrast, correlates with weight loss and reduced survival of cancer patients 
[90-93]. Interestingly, TNF promotes IL-6 secretion, and both synergize in several 
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activities [51]. IL-6 induces skeletal muscle wasting in several murine models of cancer 
cachexia, through induction of UPS and autophagy, and inhibition of mTORC1 pathway 
[95]. Moreover, IL-6 stimulates acute phase response (APR) [92, 95], and browning of WAT 
by increase UCP1 expression [96], while its role in lipid mobilization from adipose tissue is 
still debated [53]. Recently, based on encouraging results on animal models [97, 98], 
clinical trials revealed that the blockade of IL-6 pathway in cancer patients ameliorates 
some cachectic symptoms [95]. However, also IL-6 exerts different and contrasting roles, at 
least in skeletal muscle. Indeed, although IL-6 triggers severe muscle wasting in certain 
conditions, it is involved in myogenesis and skeletal muscle hypertrophy, and has beneficial 
effects on energy metabolism [99]. It is possible that detrimental effects of IL-6 rely on a 
persistent and systemic stimulation with this cytokine, and/or on a synergy of IL-6 with 
other factors [99].  
 
Furthermore, other key mediators of skeletal muscle wasting in cancer cachexia are myostatin and 
activin A, both activating the activin receptor type II B (ActRIIB) [53]. Indeed, it has been 
demonstrated that the activity of this receptor increases in different tumors [100-103]. Myostatin 
induces skeletal muscle wasting and inhibits the expression of genes associated with muscle 
differentiation, such as MyoD and myogenin [19, 21]. Interestingly, the blockade of ActRIIB is one 
of the most promising therapeutic strategies for cancer cachexia. Indeed, ActRIIB antagonism 
effectively counteracts cancer cachexia and, importantly, improves survival [104]. In cancer 
cachexia also angiotensin II (ANGII) may contribute to skeletal muscle wasting. Indeed, it has been 
reported that infusion of ANGII results in a severe lean body mass depletion, together with an 
anorexigenic response [105]. ANGII both upregulates UPS activity and impairs muscle regeneration 
[106]. 
Furthermore, additional mechanisms, affected by inflammation and other factors, are involved in 
cancer cachexia, including anorexia, abnormal metabolism and energy expenditure, and elevated 
glucocorticoids [50, 51, 53].  
 Anorexia is often associated with cancer cachexia, although it seems that there is no a 
cause-effect relationship between them [51]. Cancer cachexia and starvation differ for 
several aspects: for example non-muscle protein compartment is less affected during 
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cancer cachexia compared to starvation, and, importantly, wasting observed in cachexia 
cannot be reversed by nutritional supplementation [51]. Anorexia in cancer is likely a result 
of an unbalance between orexigenic and anorexigenic signals, accounted by different 
neuropeptides, in response to inflammatory cytokines, leptin and other mediators [107]. 
Hence, although non always present, anorexia is an important component of cancer 
cachexia, but it barely contributes directly to skeletal muscle wasting [51].  
 
 Energy expenditure and hypermetabolism, associated with the presence of systemic 
inflammation and elevated adrenergic state [108, 109], significantly contribute to cancer 
cachexia [50, 53]. Indeed, patients on total parenteral nutrition still suffer of weight loss 
and other symptoms [110]. In cancer cachexia energy is dissipated by futile cycles, such as 
Cori cycle, and by thermogenesis due to upregulation of UCP proteins [50]. Moreover, 
skeletal muscle mitochondria are deregulated in cancer cachexia [111], in part due to the 
activation of PGC1 by TNF-induced p38 activity. Indeed, it has been demonstrated that 
PGC1 increases expression of genes related to mitochondrial uncoupling, and thus energy 
expenditure [112]. Furthermore, PGC1 activates mitofusin 2 (MFN2) expression, that 
leads to Ca2+ deregulation, inducing muscle wasting. The energy expenditure in skeletal 
muscle may be associated also with metabolites generated by gut microbiota [113]. Finally, 
the synthesis of positive APR proteins by liver is not compensated by the downregulation 
of negative APR proteins, and this, during low food intake, leads to muscle mobilization 
and wasting [50]. Hence, the prolonged APR contributes significantly to the accelerated 
skeletal muscle mass loss [53].  
 
 Similarly, a physiologic response to stress is the induction of glucocorticoids, but elevated 
or prolonged doses of glucocorticoids induce skeletal muscle wasting, upregulating 
Atrogin-1 and MuRF1 [114]. In this contest, it may be harmful the treatment of cachexia 
symptoms with glucocorticoids, to reduce inflammation and increase appetite [50, 51].  
 
Furthermore, in cancer cachexia autonomic nervous system is deregulated, in particular the 
sympathetic branch, [115, 116], and gonadal function is impaired, leading to decrease in 
testosterone levels, negatively affecting skeletal muscle mass [107, 117]. A crucial role in cancer 
cachexia play also insulin-resistance, likely contributing to muscle wasting for the reduced anabolic 
INTRODUCTION 
 
16 
 
stimuli in response to meal [118, 119]. Finally, the two mainly affected tissues in cancer cachexia, 
skeletal muscle and adipose tissue, have a fine cross-talk mediated by myokines, adipokines, and 
free fatty acids [120]. Interestingly, it has been recently demonstrated that the genetic ablation of 
adipose triglyceride lipase impairs not only adipose tissue wasting, but also skeletal muscle 
degradation [121], and similar results were obtained with hormone-sensitive lipase null mice, 
although at lesser extent [121]. Although the factors mediating skeletal muscle and adipose tissue 
cross-talk have not been elucidated yet, several mechanisms have been proposed (Fig. 6, from 
[122]). 
 
 
Figure 6: Cross-talk between WAT and skeletal muscle during cancer cachexia [122] 
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In conclusion, cancer cachexia is a highly complex and multifactorial syndrome, that needs to 
further investigations to better understand the molecular mechanisms underlying its 
pathogenesis. However, as discussed above, “common themes emerge in terms of 
cytokine/neuroendocrine-driven changes in food intake, energy expenditure, adipocyte lipolysis, 
and altered hepatic and skeletal muscle protein synthesis/degradation” [53]. It is likely that 
targeting one factor could be not efficacious in counteracting cancer cachexia, and a multi-target 
approach may be the correct path. Consistently, one promising approach appears to take 
advantage from the multiple functions of ghrelin hormone. Indeed, it has just concluded a Phase 
III clinical trial with anamorelin, a ghrelin analog, that revealed benefits in cachectic conditions of 
non-small-cell lung cancer (NSCLC) patients (ESMO 27/09/2014 Press Release: Anamorelin Shown 
to Improve Appetite and Body Mass in Patients with Cancer Anorexia-Cachexia).  
 
 
Ghrelin 
Acylated ghrelin (AG) is a circulating peptide hormone, released mainly from X/A-like stomach 
cells, discovered as the endogenous ligand of GHSR-1a, a G protein-coupled receptor known for its 
ability to induce growth hormone (GH)-release upon stimulation with synthetic compounds, 
named GH-secretagogues [123, 124]. As illustrated in Fig. 7 (from [125]), human ghrelin gene, 
GHRL, has two distinct transcriptional initiation sites, leading to transcript A and transcript B [126]. 
In humans, transcript A is the main form and encodes for the 117-aminoacid long preproghrelin 
[127]. Preproghrelin is cleaved into proghrelin (1-94) and 23-aminoacid long signal peptide by 
signal peptidase [128]. Proghrelin is further processed into mature ghrelin (1-28) by prohormone 
convertase 1/3 (PC1/3) [129]. The acylation with octanoic acid or, rarely, with decanoic or 
decenoic acids [128], seems to occur in the endoplasmic reticulum on the Ser3 of proghrelin 
peptide [130], and is mediated by the ghrelin O-acyl transferase (GOAT, a member of membrane-
bound O-acyl transferases, MBOAT) [131, 132]. Interestingly, AG is the only known acylated 
peptide hormone [128]. Besides AG, also the unacylated form of ghrelin (UnAG) is released in 
circulation, and represents 90% of plasma ghrelin. Other peptides derives from ghrelin gene, by 
alternative splicing, although their function is largely unknown [133]. Notably, the C-terminal 
portion released from proghrelin cleavage is further processed into obestatin, a biological active 
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peptide originated by ghrelin gene. Obestatin was originally discovered as an antagonist of AG in 
the regulation of food intake through the activation of GPR39 orphan receptor [134], however the 
functions and receptor of obestatin are still controversial [135-138]. 
 
 
 
Figure 7: Structure of human GHRL gene and processing steps to mature ghrelin peptides [125] 
 
 
The acylation of ghrelin is crucial for the binding to GHSR-1a [123], therefore GOAT is a crucial 
enzyme for AG activities. It has been reported that GOAT likely utilizes the most available fatty 
acid substrate for ghrelin acylation [138], and that the ingestion of medium-chain fatty acids or 
triglycerides enhances ghrelin acylation [139, 140]. Interestingly, GOAT mRNA is positively 
regulated by leptin administration, and the increase of GOAT expression in chronic restricted-
nutritional conditions may account partially for the elevation of circulating AG [141, 142]. GOAT 
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knockout mice show different responses depending on the type of diet [128]. Hence, the 
regulation of ghrelin acylation by feeding behavior appears to be consistent to the stimulating 
activity of AG of food intake, adiposity and positive energy balance [143, 144]. Indeed, AG is the so 
called “hunger hormone”, raising during fasting, and frequently deregulated in pathologies 
affecting body mass and/or body energy metabolism [145, 146]. However, the circulating peak of 
AG before meal may be an anticipation of eating, rather than a stimulation of feeding [147]. 
Indeed, it has been proposed that GOAT-ghrelin system is not only a feeding stimulus reflecting an 
empty stomach, but is a sensor that signals to the brain that nutrients are available [148]. 
Consistently, among other functions, AG induces GH-release and adiposity [123, 124, 143, 149], 
that are activities not suitable in fasting conditions [148]. Fasting affects differentially circulating 
AG and UnAG levels: although AG levels do not change, gastric GOAT decreases significantly, and 
UnAG circulating levels are strongly up-regulated [148]. Indeed, it has been reported that long-
term fasting inhibits acylation, whereas it does not affect total secretion [150]. In contrast, feeding 
decreases secretion of both AG and UnAG [150]. These results suggest that secretion  may be 
independent from acylation, which results from esterases activity, cleaving the acyl group, or by 
availability of nutrient [150]. Interestingly, it has been recently demonstrated that the GOAT and 
ghrelin gene are regulated by different transcriptional factors, enforcing the idea of a uncoupling 
between ghrelin expression and acylation [151]. 
AG is the only known peripheral peptide that acts centrally in the hypothalamus regulating food 
intake [128]. Notably, both Ghsr and Ghrl knockout mice show feeding behavior similar to WT 
mice [152, 153]. Besides the GH-releasing activity of AG, acting directly in the pituitary and 
hypothalamus [123, 124, 149], AG-GHSR-1a axis affects a plethora of other tissues and systems: 
stimulates prolactin (PRL) and proopiomelanocortin (POMC) secretion, affects gastric acid 
secretion and gastric emptying, exerts neuro- and cardio-protective actions, induces bone 
formation, controls female and male reproductive physiology, inhibits inflammation, and 
decreases insulin sensitivity [128, 133]. In the context of cancer cachexia, beside the activities on 
food intake, GH release, and energy balance, it is extremely relevant the strong anti-inflammatory 
properties exerted by in several conditions [154]. In particular, it has been shown that AG, through 
GHSR-1a, inhibits pro-inflammatory cytokines expression in T lymphocytes and monocytes, 
counteracting leptin actions [155, 156]. Moreover, AG is crucial in the maintenance of thymus 
functionality during aging [157], enforcing the concept that AG exerts key actions in immune 
system. Although the main source of ghrelin is the stomach, the -islets in the pancreas produce 
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and release ghrelin [158], In addition, also the - and -islets synthetize ghrelin [159-161], 
suggesting a key role of ghrelin in the regulation of endocrine pancreas. Indeed, AG inhibits insulin 
release in mice, rats and humans [133], and affects also glucagon synthesis and release [162]. 
Moreover, AG induces peripheral insulin resistance [163, 164], and insulin negatively affects 
ghrelin levels [165-168], although it has been published contrasting results [169-171]. Finally, AG 
stimulates glycogenolysis and gluconeogenesis, preventing the inhibitory effects of insulin on 
glucose production [172-174]. Notably, the ablation of either Ghrl, or Ghsr, or GOAT genes affects 
only marginally mice phenotype under standard diet, but induces important differences in 
regulation of body weight, adiposity and glucose levels during high-fat diet or calorie restriction 
[175, 176], suggesting that the major physiological role of ghrelin system may be the control of 
glucose and weight. 
 
 
 
Figure 8: The acylation of ghrelin is necessary for the binding to GHSR1a (adapted from [179]) 
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The unacylated form of ghrelin arises from the same AG precursor, but it lacks the fatty acid 
modification, making UnAG unable to activate GHSR-1a [123]. UnAG is far more abundant in 
plasma than AG, and, since it does not bind to GHSR-1a, and thus is devoid of any GH-releasing 
activity [177, 178], has been considered for many years the inactive product of ghrelin catabolism 
(Fig. 8, adapted from [179]). AG and UnAG relative levels are finely regulated by multiple 
mechanisms, such as GOAT activity and AG deacylation mediated by acyl-protein thioesterase 
1/lysophospholipase I enzyme [180]. Moreover, it has been reported that in stomach mucosa the 
staining of AG and UnAG co-localizes in close-type round cells, whereas only UnAG is present in 
the open-type cells [181], suggesting that in the stomach different cell types are specialized in the 
production and release of AG and/or UnAG, pointing out a different biological significance of the 
two peptides. Indeed, several reports demonstrated that UnAG owns several biological activities, 
mediated by still unknown receptor(s). Besides the ability of UnAG to activate GHSR-1a in supra-
physiological concentrations [177, 182, 183], UnAG shares with AG several activities also in cells 
lacking GHSR-1a [184-192], suggesting the existence of a common receptor, still unknown. 
Moreover, it has been demonstrated that UnAG negatively affects some AG actions both in vitro 
and in vivo [172, 193, 194], , or exerts own activities [195]. It has been reported that UnAG affects 
also food intake, in a mechanism likely independent from GHSR-1a [196-198]. UnAG shares with 
AG common binding sites on several cell types, regulating differentiation [189, 199-202], 
proliferation [186, 189, 190, 203-205], and anti-apoptotic/protective pathways [184, 190, 204, 
206-209]. In contrast to AG, UnAG improves insulin sensitivity and inhibits the liver production of 
glucose [172, 210]. Interestingly, it has been observed in healthy human subjects that the injection 
of AG directly in skeletal muscle ameliorates insulin sensitivity, increasing glucose uptake [211]. 
Besides the interesting authors speculation about a second messenger affecting AG activity on 
glucose when it is injected systemically, their results suggest that the direct action of AG on 
skeletal muscle might be mediated by a still unidentified receptor. Indeed, it has been reported 
that skeletal muscle does not express GHSR-1a [212], which mediates the diabetogenic effects of 
systemically AG. 
Since AG and UnAG activate the anti-atrophic PI3K/Akt pathway in several cell types [184, 186, 
190, 204, 206], and it has been demonstrated that both peptides promote myoblast 
differentiation [189], in our laboratory raised the hypothesis that AG and UnAG could protect 
skeletal muscle from atrophy. Interestingly, in both human patients and experimental models, AG 
improves cachexia induced by several pathological conditions [213-220]. However, it reasonable 
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assume that anti-cachectic activity is mainly dependent on its GHSR-1a-mediated orexigenic, GH-
secretagogue, and anti-inflammatory activities. However, we found that: 
 in C2C12 myotubes, AG and UnAG inhibit dexamethasone-induced skeletal muscle atrophy 
through activation of a novel common receptor (herein referred as “GhrlR2”), triggering 
PI3K/mTORC2 and p38 pathways, without stimulating mTORC1-mediated stimulation of 
S6K, protein synthesis, and hypertrophy, nor regulating myostatin expression; 
 upregulation of circulating UnAG, obtained both in transgenic mice and by pharmacological 
treatment, impairs skeletal muscle atrophy induced by either fasting or denervation, 
without stimulating muscle hypertrophy, GHSR1-mediated activation of the GH/IGF-1 axis, 
and food intake;  
 UnAG administration rapidly activates anti-atrophic signaling pathways in skeletal muscle; 
 in GHSR1-/- mice, both AG and UnAG induce phosphorylation of Akt, FoxO3A and p38 in the 
skeletal muscle, and impair fasting-induced atrophy.  
 
Hence, the anti-cachectic activities of AG may be attributable also to the direct protection of 
skeletal muscle in a GHSR-1a-independent manner, through a pathway not overlapping with IGF-1 
(Fig. 9, from [221]). These data have been published in 2013 in the Journal of Clinical Investigation 
(Porporato, 2013), and are presented in the first part of the results of this thesis. For further 
details, refer to the paper in attachment.  
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Figure 9: Anti-atrophic activities triggered by AG and UnAG in skeletal muscle, through GhrlR2 [221] 
 
 
Furthermore, UnAG reduces burn-induced skeletal muscle proteolysis and local TNFα 
upregulation, and diminishes TNF/IFN-induced cachexia in C2C12 myotubes [222]. Moreover, it 
has been reported that UnAG counteracts pro-inflammatory cytokines expression induced by 
insoluble fibrillary -amyloid protein deposition in mice microglia [223], and that both AG and 
UnAG show anti-hyperalgesic and anti-inflammatory activities in rats [224]. Hence, although the 
role of UnAG on inflammation is not well investigated, these results suggest an inhibitory action of 
UnAG on inflammatory response. Thus, considering all these data, also UnAG may be take into 
account for cancer cachexia treatment [221]. Although UnAG lacks of orexigenic and GH-releasing 
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activity of AG, the clinical use of UnAG appears advantageous compared to AG, allowing directly 
skeletal muscle protection, without the diabetogenic side effects of AG and the potential cancer 
risk associated with IGF-1 treatment [210, 225]. 
In the second part of this thesis, we provide evidences of a ghrelin resistance thorugh the GhrlR2 
in cancer cachexia. Indeed, although AG treatment counteracts cachexia both in humans and 
animals [213-220], its circulating concentration is upregulated in cachectic patients, independently 
from the underlying phatology [226-232], suggesting a compensative mechanism to a reduced AG 
response. Consistently, in cancer cachexia appetite does note correlate with AG levels [233], and 
only high dose of AG affects food intake in eicosanoid-related cachexia [234]. Moreover, heart 
failure-associated cachexia display ghrelin resistance, which is reverted upon heart transplantation 
in a small group of patients [235]. These findings, along with our demonstration that both AG and 
UnAG prevent protein degradation through GhrlR2, suggest that the establishment of a resistance 
to AG/UnAG activities may contribute to the development of cancer-induced muscle wasting.  
Since our data support that GhrlR2 is a G protein-coupled receptor (GPCR) activating adenylate 
cyclase, we hypothesize that AG and UnAG signaling in the skeletal muscle might be desensitized 
through a mechanism dependent on the phosphoinositide 3-kinase gamma (PI3K), as reported for 
-adrenergic receptors [236].  
 
 
Phosphoinositide 3-kinase gamma (PI3K) 
Phosphoinositide 3-kinases (PI3Ks) are enzymes that catalyze the conversion of PtdIns(4,5)P2 to 
PtdIns(3,4,5)P3 in response to several stimuli. Based on biochemical and structure characteristics, 
PI3Ks are subdivided into three classes: PI3Ks regulated by receptors belong into class I, PI3K-C2 
kinases into class II, and the PtdIns-specific enzyme Vps34 into class III [237]. Class I members are 
characterized by the association of a catalytic subunit (p110, p110, p110, p110) with a 
regulatory subunit (5 distinct p85 isoforms, p101, and p84/87). All the p85 isoforms have a Src-
homology 2 (SH2) domain, binding to phosphotyrosines, and associate with p110, p110 and 
p110. In contrast, p110 associates with either p101 or p84/87 regulatory subunits, both lacking 
SH2 domain. For these reasons, class I is further divided into class IA (PI3K, PI3K, PI3K), 
downstream Tyr-kinase receptors (RTKs), and class IB (PI3K), downstream GPCRs [238, 239]. 
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However, it has been demonstrated that PI3K is mainly activated upon GPCR-stimulation [240], 
and it is redundant with PI3K that, in turn, can be signal downstream also RTKs [241]. Currently, 
PI3K and PI3K are considered the main isoforms activated by RTKs, while PI3K and PI3K by 
GPCRs, despite a certain grade of promiscuity [237, 238, 241], as illustrated in Fig. 9, from [238]).  
 
 
 
 
Figure 10: Upstream signals regulating Class I PI3Ks [238] 
 
 
PI3K and PI3K isoforms are heterodimers with distinct regulatory subunits, p85 and p101/p87, 
respectively, and both are activated by GPCRs. However, their role in GPCR signaling appears to be 
distinct, at least when PI3K is not greatly expressed, regulating reciprocally the downstream 
signaling upon ligand stimulation. Although PI3K is ubiquitously expressed, PI3K is the main 
isoform in white blood cells [239]. Consistently, PI3K null mice show clear defects when immune 
system is stressed [242-244]. PI3K regulates several pathways, such as Akt, JNK, Ras, and MAPK 
[245-247], and controls -AR resensitization and internalization after stimulation [248-251]. 
Interestingly, PI3K kinase-dependent and -independent actions are involved in the pathologic 
response to heart failure [252]. In the healthy heart, the role of PI3K remains negligible given its 
low expression level and its rapid inhibition after receptor stimulation. Conversely, PI3K is the 
major PI3K accountable for PIP3-mediated Akt activation in response to -AR stimulation. 
However, in stress conditions, such as hypertension and pressure overload, PI3K exerts a 
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detrimental response to cardiac stress [253]. Indeed, it has been shown that the PI3K regulatory 
subunit p84/87 physiologically acts as a scaffolding protein by supporting a macromolecular 
complex that includes p110, protein kinase A (PKA) and cAMP-phosphodiesterases (PDEs). PI3K 
is necessary to coordinate PDE activity by allowing to the active PKA to phosphorylate PDE3B. 
Moreover, p110 is inhibited by PKA-induced phosphorylation, leading to a negative feedback 
after -AR stimulation, to restore receptor density at the plasma membrane [236]. However, 
p110 can escape from PKA-mediated inhibition through the association with p101, the second 
regulatory subunit of PI3K, which is unable to associate with PKA [236]. These mechanisms have 
been clearly shown in the myocardial response to heart failure [236]. During heart failure, an 
upregulation of p101 expression instead of p84/87 leads to an increased PI3K activity, resulting in 
a strong desensitization and downregulation of -ARs at the plasma membrane [236]. In this 
context, pharmacological inhibition of PI3K kinase activity restores -AR density in heart failure, 
improving compromised cardiac contractility [236].  
In conclusion, the mutual role of PI3K and PI3K in -AR signaling may be a model for other 
receptors similar to -AR, likely other Gs-coupled receptors, in several tissue distinct to immune 
compartment, where PI3K is not the main isoform accountable for Akt activation. Consistently, 
since PI3K is upregulated by stress and inflammatory cytokines, such as IL-6, TNF, IFN, and IL-1 
[239], we hypothesized that a sustained increase of PI3K activity in cachectic muscles leads to a 
downregulation of GhrlR2, impairing ghrelin responiveness, as demonstated for -AR in heart 
failure (Fig. 11, adapted from [236]).  
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Figure 11: Model of p110/p101-mediated ghrelin resistance (adapted from [236]) 
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Materials and methods 
 
 
Reagents 
AG-(1-28) and UnAG-(1-28) were purchased from PolyPeptide Laboratories. PIK-75 hydrochloride, 
inhibitor of PI3K, was purchased from Axon Medchem; TGX-221, PI3K inhibitor was a kind gift 
from Dr. Ubaldina Galli (Synthetic Medicinal Chemistry group, Università del Piemonte Orientale, 
Novara, Italy); AS605240 and H89, PI3K and PKA inhibitor, respectively, were a kind gift from Prof. 
Emilio Hirsch (Università di Torino, Italy). Water-soluble dexamethasone, as well as other reagents, 
was from Sigma-Aldrich, unless otherwise stated. Anti-phospho-AktS473, anti-phospho-S6KT389, anti-
phospho-S6S235/236 were from Cell Signaling Technology; anti-actin and anti-GAPDH antibodies 
were from Santa Cruz Biotechnology. 
 
Mice 
All experiments were conducted on young adult (8-10 weeks) male C57BL/6J WT, PI3KKD/KD, 
Myh6/Ghrl, Ghsr-/-, and Ghrl-/- mice, matched for age and weight. Mice were handled following the 
OACU-ARAC guidelines (NIH, Office of Animal Care and Use). All animal manipulations were done 
under anesthesia with sevoflurane (Baxter). 
Cachexia was induced by subcutaneous injection of 5*106 LLC cells suspended in PBS [72, 254]. 
Mice and food intake were daily monitored, and the animals were euthanatized after 23-24 days 
from tumor cells injection [72]. The denervation-induced muscle atrophy was obtained by 
resection of the sciatic nerve of one hindlimb (Porporato, 2013), and evaluated 7 days later. 
Fasting-induced atrophy was achieved by 48-hour of food removal [255]. 
Skeletal muscle force was assessed using the BS-GRIP Grip Meter (2Biological Instruments). Each 
animal was tested 5 times, and the average value of the maximum weight that the animal 
managed to hold was recorded and normalized to the mouse’s weight. 
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Blood was collected from retro-orbital sinus/plexus, in presence of EDTA (1 mM final 
concentration) and p-hydroxymercuribenzoic acid (1 mM final concentration) to prevent ghrelin 
degradation by proteases, and centrifuged at 3,500 rpm for 10 min at 4°C. Supernatant was split 
for UnAG and AG quantification. HCl was added to AG samples (0.1 N final concentration), that 
were then centrifuged at 3,500 rpm for 5 min at 4°C. Supernatant was then transferred in a new 
tube. Plasma sample was stored at -80°C prior to be assayed.  
 
Cell cultures and myotubes analysis 
C2C12 myotubes are a widely used model to study skeletal muscle wasting in vitro [40, 42, 45, 222, 
256-258]. C2C12 myoblasts were maintained in Growth Medium (GM, DMEM 20% FBS) and 
differentiated in myotubes as previously described [189]. C2C12 myoblasts were transfected with 
Lipofectamine2000 (Life Technologies), according to the manufacturer’s protocol. To induce 
muscle wasting, C2C12 myotubes were treated for 24h in differentiation medium (DM, DMEM 2% 
horse serum), in the presence or absence of 10 nM AG or UnAG [189], or 10 ng/ml IGF-1, with: 1 
M dexamethasone [40, 42, 45, 256]; 5 or 10 ng/ml each TNF and IFN combination [222, 257]; 
20 or 100 ng/ml IL-6 [95, 98, 259]. For myotubes diameter measurement, myotubes were fixed 
with acetone:methanol (1:1) and diameters were quantified by measuring a total of about 80 
diameters from seven random fields in 3 replicates at 20X magnification using Image-Pro Plus 
software (MediaCybernetics). 
C26 adenocarcinoma cells were grown in DMEM 5% FBS, and Lewis lung carcinoma (LLC) cells 
were maintained in DMEM 10% FBS [72, 258].  
 
Muscle sampling and staining for fiber size assessment  
Collected muscles were frozen in liquid nitrogen-cooled isopentane. Serial transverse cryosections 
(7 μm thick) of the midbelly region of muscles were cut at –20°C and mounted on glass slides 
(Super Frost ultra plus, Bio-optica). The sections were fixed for 10 min in 4% paraformaldehyde at 
4°C, permeabilized with PBS 0.1% BSA-0.2% Triton X-100 for 15 min, and incubated with anti-
laminin  polyclonal antibody (Dako) for 90 min at room temperature. Therefore, sections were 
incubated for 1 h with anti-rabbit secondary antibody (Alexa Fluor 488 anti-rabbit IgG) at room 
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temperature. Images of whole muscles were acquired with Pannoramic Digital Slide Scanners 
(3DHISTECH), and fibers minimal Feret’s diameter [260] were measured automatically with 
ImageProPlus (Media Cybernetics). Data are expressed as frequency distribution of myofibers 
diameter. 
 
Conditioned medium (CM) preparation  
For CCM and LCM collection, from C26 and LLC cells supernatant, respectively, cells were seeded 
at a density of 5*105 cells/cm2 and, after overnight attachment, were washed three times with 
PBS, followed by two washes with serum-free DMEM, and grown in serum-free DMEM for 24h. 
The resulting CCM/LCM was centrifuged at 500 g for 10 min, followed by an additional 
centrifugation at 5,000 g for 10 min. The CCM/LCM was filtered using a 0.2 μm syringe filter and 
either stored at -80°C or used immediately [258].   
 
RNA extraction and analysis 
Total RNA from cultured myotubes or frozen muscles was extracted with TRIreagent (Life 
Technologies). RNA was retro-transcribed with High Capacity cDNA Reverse Transcription Kit (Life 
Technologies) and real-time PCR was performed with the ABI7200 Sequence Detection System 
(Life Technologies) using the following assays: Mm00499518_m1 (Fbxo32, Atrogin-1/MAFbx), 
Mm01185221_m1 (Trim63, MuRF1), Mm004450358_m1 (Pik3cg, p110 catalytic subunit), 
Mm00805205_m1 (Pik3r5, p101 regulatory subunit), Mm01335671_m1 (Pik3r6, p84/87 regulatory 
subunit), Mm00446953_m1 (Gusb), Mm00506384_m1 (Ppif), Mm01205647_g1 (Actb, -actin). 
 
Western Blot 
C2C12 myotubes were serum-deprived overnight and then treated as indicated. Cells were 
washed with PBS 1X containing 1 mM Na3VO4, and then homogenized in RIPA buffer (1% Triton X-
100, 1% sodium-deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM EGTA, 59 mM NaF, 160 mM NaCl and 
20 mM Tris-HCl pH 7.4) containing 1 mM DTT, Protease Inhibitors Cocktail, and 1 mM Na3VO4. The 
homogenates were centrifuged at 14,000 g for 15 min to remove the debris and nuclei. The 
MATERIALS AND METHODS 
 
31 
 
supernatant were mixed with SDS loading buffer 3X (187.5 mM Tris-HCl pH 6.8, 6% w/v SDS, 30% 
glycerol and 0.03% w/v bromophenol blue) and boiled at 95°C for 5 min. The electrophoresis was 
performed with 8-10% polyacrylamide gel (Sigma Aldrich), and then the proteins were transferred 
on PVDF membranes (Hybond-P, GE Healthcare). After 1-hour of saturation in 3% BSA at room 
temperature, the membranes were incubated with primary antibody overnight at 4°C, and then 
with secondary antibody for 1h at room temperature. Finally, the membranes were visualized with 
Western Lightning Chemiluminescence Reagent Plus (PerkinElmer Life Sciences) and analyzed with 
Quantity One software (Bio-Rad).  
 
Intracellular cAMP measurement 
C2C12 myotubes were serum-deprived for 18h, and then treated for 5 min with 1 M AG and 
UnAG in the presence of 100 M IBMX (3-Isobutyl-1-methylxanthine, phosphodiesterase 
inhibitor). 1 M CGS, agonist of adenosine receptor A2A, was used as positive control. Assay was 
performed following the producer’s protocol (Cayman Chemical). 
 
Ghrelin ELISA 
Plasma AG and UnAG levels was measured by EIA kits (SPIbio Bertin Pharma), according to the 
manufacturer’s instructions. 
 
Statistical analysis 
Data are presented as the mean ± SEM, or box and whiskers plots showing median (black line) and 
Min and Max (whiskers). The variation among groups was evaluated using Wilcoxon and Mann-
Whitney U tests. Statistical significance was assumed for P < 0.05.  
 
 
For further details about results published in Porporato, 2013, refer to the attached paper. 
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AG and UnAG counteract skeletal muscle atrophy in vitro in a PI3K/mTORC2-, p38-, and 
cAMP/PKA-dependent manner 
In our lab it has been demonstrated that AG and UnAG inhibit apoptotis in cardiomyocytes and 
promote myoblasts differentiation, by activating a novel receptor distinct from GHSR-1a [184, 
189]. Moreover, in several cell types AG and UnAG trigger PI3K/Akt pathway [184, 190, 204, 206], 
that is the major hypertrophic and anti/atrophic signaling in skeletal muscle. Hence, we decided to 
test the hypothesis that both peptides may counteract skeletal muscle atrophy. After 24-hour 
treatment of C2C12 myotubes with the synthetic glucocorticoid dexamethasone, a widely adopted 
model to assay atrophy in vitro, we measured myotubes diameter, and Atrogin-1 and MuRF1 
expression [40, 42, 45, 256]. We demonstrated that AG and UnAG counteract dexamethasone-
induced atrophy, without inducing hypertrophy, in contrast to IGF-1 (Fig. 12, A-C). Moreover, both 
wortmannin (W) and rapamycin (R) blunt AG and UnAG activities, suggesting the involvement of 
the PI3K/mTOR pathway (Fig. 12D). Rapamycin is an inhibitor of mTOR complex 1 (mTORC1), 
which leads to protein synthesis stimulation, but upon long treatment also of mTOR complex 2 
(mTORC2), which inhibits protein degradation [261-263]. Indeed, we showed that both peptides 
increase AktS473 and FoxO3aT32 phosphorylation, markers of mTORC2 activity, while do not induce, 
in contrast to IGF-1, mTORC1-associated S6KT389 and S6S235/236 phosphorylation, and leucine 
incorporation (Fig. 12, E-I). Accordingly, the knockdown of raptor and rictor, the specific 
components of mTORC1 and mTORC2, respectively, differently affects AG/UnAG and IGF-1 anti-
atrophic activity: the silencing of raptor impairs IGF-1 action, while does not affect that of AG and 
UnAG; conversely, the knockdown of rictor blunts AG and UnAG activity, affecting to a lesser 
extent that of IGF-1 (Fig. 1, J and K). These data demonstrate that AG and UnAG activate 
selectively mTORC2 pathway, leading to inhibition of protein degradation, without stimulation of 
mTORC1 and protein synthesis. 
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Figure 12 (from Porporato, 2013): AG and UnAG protect C2C12 myotubes from dexamethasone-induced atrophy 
without induction of protein synthesis or hypertrophy. (A) Myotubes diameter was measured after 24-hour 
treatment in differentiation medium (DM) with 10 nM AG, 10 nM UnAG, and/or 1 μM dexamethasone (DEXA). In 
every experiments, 10 ng/ml IGF-1 was used as positive control for anti-atrophic/hypertrophic activity. (B and C) 
Atrogin-1 and MuRF1 expression analysis upon 24-hour treatment of 1 M dexamethasone with or without 10 nM AG 
or 10 nM UnAG, determined by real-time RT-PCR. (D) Treatment with 100 nM wortmannin (W) or 20 ng/ml rapamycin 
(R) reverts the anti-atrophic activity of AG and UnAG on myotubes diameter. Control myotubes in differentiation 
medium were treated with DMSO, a vehicle for both wortmannin and rapamycin. (E and F) Phosphorylation of Akt
S473
 
and FoxO3a
T32
, detected by Western blotting, upon treatment for 20 min with 1 μM AG or UnAG. Shown are 
representative blots and quantification of 3 independent experiments. (G-I) IGF-1, but not AG and UnAG, induces 
protein synthesis, as determined by phosphorylation of S6K
T389
 (G) or S6
S235/236
 (H), and by incorporation of [
3
H]-
leucine (I). (J) Effect of raptor and rictor silencing on protein levels, detected by Western blotting. (K) Silencing of 
rictor, but not of raptor, reverts the anti-atrophic activity of AG and UnAG on the diameter of myotubes treated as in 
A. #P < 0.05, §P < 0.01 vs. DM control; *P < 0.01 vs. DEXA treatment. 
 
Furthermore, it has been demonstrated that AG and UnAG activate p38 in C2C12 myoblasts [189], 
and that p38 can variably modulate Atrogin-1 expression in different conditions [78, 264-266]. We 
observed that AG and UnAG induce p38T180/Y182 phosphorylation in C2C12 myotubes, and that p38 
inhibition with SB203580 blunts the anti-atrophic effects of both peptides (Fig. 13, A-D).  
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Figure 13 (from Porporato, 2013): AG and UnAG anti-atrophic signaling is mediated by p38. (A) Phosphorylation of 
p38
T180/Y182
, detected by Western blotting, after 20-min treatment with 1 μM AG or UnAG. Shown are representative 
blots and quantification of 3 independent experiments. (B) Treatment with the p38 inhibitor SB203580 (5 μM) reverts 
the anti-atrophic activity of AG and UnAG on myotube diameter upon treatment with dexamethasone, without 
affecting IGF-1 activity. (C and D) Atrogin-1 and MuRF1 expression analysis upon dexamethasone treatment with or 
without AG and UnAG, in the presence or absence of 5 μM SB203580. #P < 0.05, §P < 0.01 vs. DM control; *P < 0.05, 
**P < 0.01 vs. DEXA treatment. 
 
Since C2C12 myotubes do not express GHSR-1a receptor [189], these results suggest that AG and 
UnAG activate a novel common receptor, as already reported [184, 186, 189, 190, 206]. The 
receptor mediating AG and UnAG activities in -cells is unaffected by pertussis toxin (PTX), an 
inhibitor of Gi, and, in contrast, is sensitive to NF449, a Gs-uncoupling drug, suggesting that the 
novel receptor is bona fide a Gs-coupled receptor [190]. Moreover, both AG and UnAG induce 
cAMP synthesis in -cells [190]. Consistently, in C2C12 myotubes we demonstrated that NF449 
inhibits AG/UnAG-induced AktS473 phosphorylation and anti-atrophic activity, without affecting 
IGF-1 signaling (Fig. 14, A and B). In addition, both AG and UnAG rapidly increase intracellular 
concentration of cAMP (Fig. 14C), that, in turn, activates PKA, which is necessary for AG/UnAG 
anti-atrophic activities, as revealed by the loss of efficacy of both peptides in the presence of PKA-
specific inhibitor H89 (Fig. 14D). In contrast, PTX do not affect AG and UnAG response (Fig. 14E). 
Interestingly, we demonstrated that the specific isoform of PI3K necessary to AG/UnAG anti-
atrophic activity is PI3K (Fig. 14, F and G), which mediates Akt activation mainly upon GPCRs 
activation [238]. In contrast, PI3K, associated with RTKs [238], is crucial for IGF-1 response but 
does not affect that of AG and UnAG (Fig. 14F). 
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Figure 14 (from Porporato, 2013 and unpublished): AG and UnAG activate a Gs-coupled receptor. (A) AG and UnAG 
phosphorylation of Akt
S473
 is abolished upon treatment with 10 μM NF449, a Gαs subunit–selective G protein 
antagonist. Shown are representative blots and quantification of 3 independent experiments. (B) Treatment with 10 
μM NF449 reverts the anti-atrophic activity of AG and UnAG on myotubes diameter upon dexamethasone treatment. 
(C) Treatment for 5 min with 1 M AG or UnAG increases intracellular cAMP concentration. CGS, an agonist of 
AdoraA2A receptors, was used as positive control of Gαs agonist. (D and E) Anti-atrophic activity of AG and UnAG on 
myotubes diameter upon dexamethasone treatment is abolished by the treatment with 2.5 g/ml H89, a PKA inhibitor 
(D), but unaffected by 100 nM pertussis toxin (PTX), a Gαi inhibitor (E). (F) Treatment with 25 nM PIK-75, an inhibitor 
of PI3Kα, blunts the anti-atrophic effect of IGF-1 on myotubes diameter upon dexamethasone treatment, without 
affecting AG and UnAG activity. Conversely, the anti-atrophic effect of AG and UnAG is abrogated by treatment with 
200 nM TGX-221, an inhibitor of PI3Kβ. (G) Atrogin-1 expression analysis upon dexamethasone treatment with AG, 
UnAG, and IGF-1 in the presence or absence of 200 nM TGX-221. In experiments with NF449, H89, PIK-75, and TGX-
221, control myotubes in differentiation medium were treated with DMSO, a vehicle for all these compounds. #P < 
0.05, §P < 0.01 vs. DM control; *P < 0.05, **P < 0.01 vs. DEXA treatment. 
 
All these data demonstrate that AG and UnAG, by activating a novel common receptor distinct to 
GHSR-1a, herein referred as “GhrlR2”, stimulate an anti-atrophic signaling pathway in C2C12 
myotubes, without inducing hypertrophy and protein synthesis, thus only partially overlapping 
with IGF-1 pathway (Fig. 15). 
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Figure 15: Signaling pathway of AG and UnAG mediating their anti-atrophic activity in skeletal muscle. 
Representative cartoon of the anti-atrophic pathway triggered by AG and UnAG summarizing the results obtained in 
C2C12 myotubes. Ghrelin peptides counteract skeletal muscle atrophy activating a novel common receptor, that, in 
turn, induces cAMP/PKA, PI3K/mTORC2/Akt, and p38 signaling pathways, leading to the inhibition of protein 
degradation, without affecting mTORC1 and protein synthesis.  
 
 
UnAG impairs denervation- and starvation-induced skeletal muscle atrophy 
To investigate the ability of ghrelin to impair muscle wasting in vivo, by acting directly on skeletal 
muscle, we utilized UnAG to avoid the confounding effect of the GHSR-1a/GH/IGF-1 axis triggered 
by AG. We generated a transgenic mice line (Tg) overexpressing the Ghrl gene under a specific 
cardiac promoter (Myh6/Ghrl). Ghrelin expressed in the heart is released in the blood. These mice 
are characterized by 50-fold increase in circulating UnAG, without affecting AG concentration (for 
a detailed description of Myh6/Ghrl mice phenotype refer to the attached paper Porporato, 2013). 
Notably, these mice do not feature hypertrophy in skeletal muscle, consistently with the inability 
of UnAG to induce hypertrophy in C2C12 myotubes (Fig. 12A). We demonstrated that Myh6/Ghrl 
mice are protected from muscle wasting induced by both 48-hour of food deprivation (Fig. 16, A-E) 
and sciatic nerve resection (Fig. 16, F-K).  
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Figure 16 (from Porporato, 2013): Myh6/Ghrl mice are protected from skeletal muscle atrophy induced by either 48 
hours of fasting or sciatic nerve resection. (A-E) Effect of fasting on gastrocnemii. Mean percentage of gastrocnemius 
weight loss (A) and cross-sectional area (CSA) reduction (B) of fasted Myh6/Ghrl  (Tg) mice and WT littermates 
compared with fed animals. (C) Frequency distribution of gastrocnemii CSA  of fasted Myh6/Ghrl and WT mice. (D and 
E) Atrogin-1 and MuRF1 expression in gastrocnemii of fed and fasted Myh6/Ghrl mice and their WT littermates, 
determined by real-time RT-PCR. N = 7 (fed WT and Myh6/Ghrl), 5 (fasted WT), 6 (fasted Myh6/Ghrl), and 3 (CSA loss 
and distribution, WT and Myh6/Ghrl). (F-K) Effect of denervation on gastrocnemii. Mean percentage of weight loss (F) 
and CSA reduction (G) of denervated gastrocnemius at 7 and 14 days after denervation, compared with the 
unperturbed side. (H and I) Frequency distribution of gastrocnemii CSA at 7 and 14 days after denervation in 
Myh6/Ghrl and WT littermates. (J and K) Atrogin-1 and MuRF1 expression in denervated gastrocnemii at 7 days after 
denervation, compared with the unperturbed side. N = 6 (WT), 5 (Myh6/Ghrl), and 3 (CSA loss and distribution, WT 
and Myh6/Ghrl). **P < 0.01, *P < 0.05 vs. WT.  
 
Furthermore, subcutaneous injection of 100 g/Kg UnAG triggers AktS473, FoxO3aT32, and 
p38T180/Y182 phosphorylation in gastrocnemii (Fig. 17, A-C). Importantly, at that concentration AG 
protects from heart failure-associated cachexia [213]. The repeated injection of 100 g/Kg UnAG 
(twice a day) is sufficient to counteract skeletal muscle atrophy induced by starvation (Fig. 17, D-F) 
and denervation (Fig. 17, G-I). These data demonstrate that UnAG rapidly activates anti-atrophic 
signaling pathways in skeletal muscle, thus protecting from muscle wasting, without involving the 
GHSR-1a/GH/IGF-1 axis. 
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Figure 17 (from Porporato, 2013): UnAG pharmacological treatment protects skeletal muscle from fasting- and 
denervation-induced atrophy in WT mice. (A-C) Phosphorylation of Akt
S473
, FoxO3a
T32
, and p38
T180/Y182
 in gastrocnemii 
of WT mice treated with 100 μg/Kg UnAG or saline. At the indicated time points, gastrocnemii were removed and 
processed for Western blot analysis. Shown are representative blots and densitometric analysis of 3 independent 
experiments, normalized to untreated animals (not shown). (D-F) Effect of fasting on gastrocnemii. Mean percent 
weight loss (D), CSA reduction (E), and CSA frequency distribution (F) of gastrocnemii from 48-hour fasted mice 
treated twice daily with 100 μg/Kg UnAG or saline (N = 5 per group). Frequency distribution was measured in 3 mice 
per group. In D and E, percent reduction shown is between fasted and fed mice. (G-I) Effect of denervation on 
gastrocnemii. Mean percent weight loss (G), CSA reduction (H), and CSA frequency distribution (I) of gastrocnemii 
from mice treated with 100 μg/Kg UnAG or saline twice daily for 7 days after sciatic nerve resection (N = 5 per group). 
CSA frequency distribution was measured in 3 mice per group. In G and H, percent reduction shown is between 
denervated gastrocnemii and gastrocnemii from the unperturbed side. *P < 0.05, **P < 0.01 vs. saline treatment. 
 
 
Both AG and UnAG impair muscle wasting in Ghsr-/- but not in WT mice 
To confirm the existence of a novel receptor, distinct from GHSR-1a, mediating the activity of 
ghrelin peptides directly in skeletal muscle, we injected subcutaneously 100 g/Kg of either AG or 
UnAG in Ghsr-/- mice, and we demonstrated that in those mice both peptides trigger AktS473 
phosphorylation in gastrocnemii (Fig. 18A). Moreover, the pharmacological treatment of either AG 
or UnAG protects from fasting-induced skeletal muscle atrophy (Fig. 18, B-D). These results are the 
first genetic proof of the existence of a novel receptor distinct from GHSR-1a, mediating activities 
of both AG and UnAG. 
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Figure 18 (from Porporato, 2013): AG and UnAG pharmacological treatment of Ghsr
-/-
 mice induces anti-atrophic 
signaling and protects from fasting-induced skeletal muscle atrophy. (A) Phosphorylation of Akt
S473
 in gastrocnemii of 
Ghsr
-/-
 mice injected with 100 μg/Kg AG or UnAG or with saline. 60 min after treatment, gastrocnemii were removed 
and processed for Western blot analysis. Shown are representative blots and densitometric analysis of 3 independent 
experiments. (B-D) Mean percentage weight loss (B), CSA reduction (C), and CSA frequency distribution (D) of 
gastrocnemii from fed or 48-hour fasted Ghsr
-/-
 mice injected s.c. twice daily with 100 μg/Kg AG or UnAG or with saline 
(N = 5 per group). Frequency distribution was measured in 3 mice per group. In B and C percent reduction is between 
fasted and fed mice. *P < 0.05, **P < 0.01 vs. saline treatment. 
 
Furthermore, we wanted to test the contribution of the GHSR-1a/GH/IGF-1 axis on the anti-
atrophic activity of ghrelin peptides, comparing AG and UnAG pharmacological treatment in WT 
mice. Surprisingly, we observed that in WT mice AG is very inefficient to counteract muscle 
wasting induced by 48-hour of food deprivation compared to UnAG (Fig. 19A), although AG-
treated mice show a moderate reduction of weight loss compared to saline- and UnAG-injected 
mice (Fig. 19B). Hence, although AG was biological active in WT mice, its treatment seems to not 
affect skeletal muscle mass, unlike UnAG. These results point out biological differences between 
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AG and UnAG, that may have crucial therapeutic implications. To further investigate this issue, we 
treated with AG, twice a day for 7 days after sciatic nerve resection, Ghsr-/- mice compared to WT. 
We confirmed that, indeed, AG exerts its beneficial effects on skeletal muscle only in Ghsr-/- mice, 
but not in WT mice (Fig. 19, C and D). These surprising results suggest that GHSR-1a signaling may 
negatively affect GhrlR2 activity in skeletal muscle, but this issue needs further investigations.    
 
 
 
Figure 19 (unpublished): The anti-atrophic activity of AG is reduced in WT mice. (A-B) Effect of AG in fasting. 
Percentage of maintenance of gastrocnemii mass (A) and body weight loss (B) induced by s.c. injection of 100 μg/Kg 
AG or UnAG twice daily during 48-hour of food deprivation (N = 7 per group). In A percent maintenance is between 
AG- or UnAG- and saline-treated mice. In B percent reduction is calculated between initial and final body weight. (C-D) 
Effect of AG in denervation. (C) Percentage of gastrocnemii weight loss after 7 days from sciatic nerve resection, 
compared with the unperturbed side. (D) Percentage of AG ability to preserve gastrocnemius mass in WT compared to 
Ghsr
-/-
 mice (N = 7 per group). *P < 0.05. 
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UnAG shows reduced anti-atrophic activity in cancer cachexia 
The finding that AG is unable to counteract skeletal muscle wasting in WT mice has important 
translational implication. Indeed, it has been demonstrated that AG counteracts cachexia both in 
animal models and in patients [213-220], therefore it is the promising first drug against this critical 
medical need. It has been just concluded a phase III clinical trial for anamorelin, an AG analog, in 
non-small-cell lung carcinoma (NSCLC) patients. The results have not been published yet, but it has 
been reported that anamorelin improved body weight, lean body mass, but not handgrip strength 
(ESMO 27/09/2014 Press Release: Anamorelin Shown to Improve Appetite and Body Mass in 
Patients with Cancer Anorexia-Cachexia). Moreover, some patients displayed side effects, such as 
gastrointestinal and metabolic disorders, hyperglycemia, and diabetes mellitus. Similar results 
have been published from two Phase II clinical trial evaluating the treatment of anamorelin for 
cancer cachexia [267]. Since anamorelin is an AG analog, it is likely that it binds also the novel 
receptor GhrlR2, although there are no data about this. However, it is reasonable assume that the 
results obtained with anamorelin depend on GHSR-1a-mediated orexigenic, GH-releasing, and 
anti-inflammatory activities. Thus, anamorelin may affect directly skeletal muscle mass only in a 
lesser extent, as pointed out by our results on AG inability to counteract muscle wasting in WT 
mice. In addition, AG owns relevant diabetogenic effects [210], and a potential cancer risk 
associated with IGF-1 release [225]. For these reasons, the anti-atrophic activity of UnAG, which 
does not bind to GHSR-1a, has relevant therapeutic perspectives, and thus we decided to test the 
ability of UnAG to preserve skeletal muscle mass during cancer cachexia. We injected 
subcutaneously 5 millions of Lewis lung carcinoma (LLC) cells in Myh6/Ghrl mice. Globally, we 
observed that cachectic Myh6/Ghrl mice are slightly better than WT, and present low grade of skin 
ulceration around the tumor mass. Consistently, we found that Myh6/Ghrl mice show a lesser 
extent of anorexia in the severe cachexia stages (Fig. 20A), while body weight loss is similar (Fig. 
20B). Notably, upregulation of circulating UnAG do not affect tumor mass (Fig. 20C). Surprisingly, 
we observed no significant differences, between WT and Myh6/Ghrl mice, in both epididymal fat 
weight (Fig. 20D), and gastrocnemii (GAS) and extensor digitorum longus (EDL) weight loss (Fig. 20, 
E and F), while only a modest improvement in tibialis anterior (TA) and quadriceps (QUAD) muscle 
mass (Fig. 20, G and H). The expression of Atrogin-1 and MuRF1 in GAS and TA further confirm the 
weak differences between WT and Myh6/Ghrl mice observed in muscles mass (Fig. 20, I-L). 
Consistently, frequency distribution of the minimal Feret’s diameter of cachectic TA myofibers 
shows a little shift of Myh6/Ghrl myofibers, compared to WT, towards bigger diameters (Fig. 20,M 
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and N). In conclusion, these data unveil a modest efficacy of UnAG in counteracting cancer 
cachexia.  
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Figure 20 (unpublished): Myh6/Ghrl mice are weakly protected from LLC-induced cachexia. (A) Daily food intake 
during cancer cachexia progression. (B-G) Comparison between WT and Myh6/Ghrl mice, at 23 days after Lewis lung 
carcinoma (LLC) cells s.c. injection, of percentage of body weight loss (B), tumor weight (C), epididymal fat weight (D), 
and percentage of gastrocnemius (E), extensor digitorum longus (F), tibialis anterior (G), and quadricep (H) weight 
loss. N = 9 (WT) and 8 (Myh/Ghrl). In E-H percent reduction shown is between non-tumor-bearing and cachectic mice. 
(I-L) Atrogin-1 (Fbox32) and MuRF1 (Trim63) expression in gastrocnemii (I and J) and tibialis anterior (K and L) of non-
tumor-bearing (CTR) and cachectic (CACHEXIA) mice. N = 3 (CTR), 6 (CACHEXIA GAS), 4 (CACHEXIA TA WT), and 8 
(CACHEXIA TA Myh6/Ghrl). (M) Representative image of laminin staining of tibialis anterior of LLC-bearing mice, for 
measurement of minimal Feret’s diameter of myofibers. (N) Frequency distribution of minimal Feret’s diameter of 
tibialis anterior myofibers of cachectic mice, automatically quantified with ImageProPlus (Media Cybernetics). N = 4 
(WT) and 5 (Myh6/Ghrl). **P < 0.01. 
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Circulating UnAG increases during cancer cachexia 
Our data suggest that the anti-cachectic activities exerted by AG may dependent mainly by GHSR-
1a-mediated orexigenic and GH-releasing effects. Moreover, AG has strong anti-inflammatory 
properties, through the activation of GHSR-1a, although it has been demonstrated that also UnAG 
downregulates inflammatory states [222-224]. However, it has been demonstrated that circulating 
AG and total ghrelin increase during cachexia, independently from the underlying pathology [226-
232]. This evidence leads to the hypothesis that in cachexia there is the establishment of an AG 
resistance, as previously reported [233-235], and that only a higher concentration of AG may 
restore its effects GHSR-1a-mediated [234]. Since these studies reported concentration of 
circulating AG or total ghrelin, we wanted to specifically investigate UnAG concentration in cancer 
cachexia models. We observed, indeed, that circulating UnAG is up-regulated in adenocarcinoma 
C26- (Filigheddu and Coletti, unpublished results) and LLC-bearing mice (Fig. 21, A and B). 
Furthermore, it has been demonstrated that ghrelin may be relevant in physiologic muscle repair. 
Indeed, at 24h from intramuscular treatment with cardiotoxin (CTX), a necrotic agent stimulating 
skeletal muscle regeneration, ghrelin precursor preproghrelin, strongly increases in injured 
muscles [268]. Moreover, UnAG induces skeletal muscle regeneration upon ischemic damage 
[195]. Since the impairment of muscle regeneration is a crucial point in the eziopathogenesis of 
muscle decay in cancer cachexia [57-61], we tested whether cachectic muscles show increased 
ghrelin expression. We observed that in cachectic TA ghrelin expression is increased, although not 
statistically significant, mainly in C26- (Filigheddu and Coletti, unpublished results) than in LLC-
bearing mice (Fig. 21, C and D). However, this finding points out the critical role of a particular 
cytokines combination regulating ghrelin expression in skeletal muscle, as an adaptive response to 
severe muscle injury. 
RESULTS 
 
48 
 
 
Figure 21 (unpublished): Ghrelin is upregulated in cancer cachexia. (A and B) Circulating levels of UnAG in non-
tumor-bearing mice (CTR) and cachectic mice bearing C26 adenocarcinoma (A) or Lewis lung carcinoma (B). N = 8 (CTR 
C26, CACHEXIA LLC) and 10 (CTR LLC and CACHEXIA C26). (C and D) Ghrelin expression in tibialis anterior of C26- (C) 
and LLC- (D) induced cachectic mice. In N = 6 (CTR C26), 10 (CACHEXIA C26), 5 (CTR LLC), and 8 (CACHEXIA C26). *P < 
0.05, **P < 0.01 vs. CTR. 
 
The increase in circulating ghrelin peptides may be the establishment of either a ghrelin 
resistance, or a compensatory mechanism, or both. Interestingly, also the tumor might release AG 
and UnAG to support its growth, similar to other factors. To investigate the physiological role of 
the upregulation of ghrelin peptides during cachexia, we studied the cachectic phenotype in Ghrl-/- 
mice. Interestingly, our results suggest that the ablation of Ghrl gene impacts only marginally 
cachexia progression. Indeed, we didn’t observed any differences in food intake (Fig. 22A), body 
weight loss (Fig. 22B), epididymal fat weight (Fig. 22C), weight loss of GAS, TA, EDL and QUAD 
muscles (Fig. 22, D-G), and forelimb force (Fig. 22H). Importantly, not only the lacking of Ghrl gene 
do not affect tumor growth (Fig. 22I), but also tumor cells do not release UnAG in the circulation, 
at least in LLC-model. Indeed, circulating UnAG remains undetectable in Ghrl-/- mice also after LLC 
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transplantation (data not shown). Although these findings do not reveal the physiological role of 
the circulating AG and UnAG upregulation, they strongly suggest that ghrelin response, mediated 
not only by GHSR-1a but also by GhrlR2, is reduced or impaired during cancer cachexia. 
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Figure 22 (unpublished): Ablation of Ghrl gene does not affect cancer cachexia progression. (A) Daily food intake 
during cancer cachexia progression. (B-G) Comparison between WT and Ghrl
-/-
 mice, at 24 days after LLC injection, of 
percentage of body weight loss (B), epididymal fat weight (C), and percentage of gastrocnemius (D), tibialis anterior 
(E), extensor digitorum longus (F), and quadricep (G) weight loss. In D-G percent reduction shown is between non-
tumor-bearing and cachectic mice. (H) Hindlimb relative force was measured with grasping test during cancer cachexia 
progression. (I) Tumor weight at 24 days after LLC cells inoculation. N = 9 (WT) and 5 (Ghrl
-/-
). 
 
 
PI3K and PI3K inversely affect ghrelin signaling 
We have demonstrated that GhrlR2 is bona fide a Gs-coupled receptor triggering PI3K/mTORC2, 
p38, and cAMP/PKA pathways. It has been demonstrated that -ARs, which are also Gs-coupled 
receptors, activate two distinct PI3K isoforms: PI3K, accountable for Akt activation, and PI3K, 
necessary to internalization of -ARs upon stimulation [236, 250]. Since the anti-atrophic activity 
of AG and UnAG is mediated by PI3K activation, similar to -ARs, and, in contrast, it has been 
shown that PI3K mediates, through Akt activation, the anti-lipolytic actions of both peptides in 
adipocytes [269],  we decided to investigate the role of PI3K in the GhrlR2-triggered signaling in 
skeletal myotubes. Surprisingly, we observed that the ability of both peptides to counteract 
dexamethasone-induced atrophy seems enhanced in the presence of AS605240, a specific 
inhibitor of PI3K (Fig. 23A). Moreover, in absence of dexamethasone, the inhibitor of PI3K makes 
AG and UnAG hypertrophic factors, increasing the size of myotubes diameter over the basal level, 
like IGF-1 (Fig. 23B). Indeed, although AG and UnAG are unable to induce S6KT389 phosphorylation 
(Fig. 12G and 23C), both peptides increase S6KT389 phosphorylation when PI3K is inhibited (Fig. 
23D), indicating mTORC1 activation, consistently with the observed hypertrophic phenotype. In 
conclusion, we showed that PI3K activity regulates AG/UnAG response, and inversely affects 
ghrelin signaling compared to PI3K, as demonstrated for -ARs.   
RESULTS 
 
52 
 
 
Figure 23 (unpublished): PI3K inhibition enhances AG and UnAG signaling in vitro. (A) C2C12 myotubes diameter 
was measured after 24-hour of dexamethasone treatment, in the presence or absence of 40 nM AS605240, a PI3K 
inhibitor, with 10 nM AG or UnAG, or 10 ng/ml IGF-1. (B) Treatment with 40 nM AS605240 makes AG and UnAG 
hypertrophic factors. (C and D) Phosphorylation of S6K
T389
, detected by Western blotting, upon 20-min treatment with 
1 μM AG or UnAG, or 10 ng/ml IGF-1, in the presence or absence of 40 nM AS605240. Shown are representative blots 
and quantification of 3 independent experiments.  §§P < 0.01 vs. DM control; **P < 0.01 vs. DEXA treatment. 
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The expression of p101 increases in cancer cachexia 
Based on our findings in C2C12 myotubes, we hypothesized that a deregulation in PI3K activity 
may affect the AG/UnAG response through GhrlR2. Indeed, it has been demonstrated for -ARs in 
heart failure that an upregulation of the PI3K regulatory subunit p101 leads to an enhanced PI3K 
activity, resulting in a strong downregulation of -ARs density at the plasma membrane [236]. 
Consistently, the catalytic inhibition of PI3K restores -ARs density [236]. Therefore, we 
hypothesized that in cancer cachexia p101 expression might increase in skeletal muscle, negatively 
affecting the density of different receptors at the plasma membrane, including GhrlR2. In LLC-
bearing mice we found, both in GAS and in TA, a tendency of p110 expression to decrease, but 
not statistically significant (Fig. 24A), and, importantly, an upregulation of p101 expression (Fig. 
24B), in contrast to that of p84/87 (Fig. 24C), leading to more than two-folds in p101/p87 ratio 
compared to controls (Fig. 24D). Interestingly, p101 expression in GAS correlates with tumor 
weight (Fig. 24E) and GAS weight loss (Fig. 24F), indicating a close connection between p101 
expression and severity of cachexia. Indeed, we found an increase in p101 expression in a time 
dependent manner from LLC-inoculation (data not shown). In conclusion, these data demonstrate 
that in cachectic muscle there are a deregulation in PI3K subunits expression, similar to that 
shown in heart failure. Hence, we hypothesized that the increased expression of p101 instead 
p84/87 in cancer cachexia leads to a downregulation of GhrlR2 at the plasma membrane, reducing 
the responsiveness to ghrelin peptides (Fig. 24G).  
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Figure 24 (unpublished): The p101 expression increases in cachectic muscles proportionally to cachexia grade. (A-D) 
PI3K subunits expression in gastrocnemii, detected by real-time RT-PCR. Comparison between non-tumor-bearing 
and cachectic mice of the expression of p110 (A), p101 (B), p84/87 (C). (D) Ratio between the expression of p101 and 
p84/87 regulatory subunits. (E and F) Correlation between p101 expression and tumor weight (E) or gastrocnemii 
weight loss (F). **P < 0.01.   
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The AG and UnAG response inversely correlates with p101 expression  
A key feature of cancer cachexia is the presence of chronic inflammatory state. Among others, 
TNF, IFN, IL-6, and IL-1 are the pro-inflammatory cytokines mainly involved in cancer cachexia 
[51]. We investigated the modulation of p101 expression in C2C12 myotubes upon 24-hour 
treatment with either TNF/IFN combination or IL-6. We observed that p101 expression 
significantly increases in TNF/IFN-treated C2C12 myotubes, but not in those treated with IL-6 
(Fig. 25A). Preliminary observations showed that AG and UnAG anti-atrophic activity is blunted or 
reduced after 24- or 48-hour treatment with LLC-conditioned medium, while is unaffected by C26-
conditioned medium (Fig. 25, B and C). Since C26- and LLC-induced cachexia is mainly due by IL-6 
and TNF, respectively, we investigated the AG and UnAG ability to impair IL-6 and TNFa effects in 
C2C12 myotubes. We demonstrated that both IL-6 and TNF/IFN treatment reduces myotubes 
size, but AG and UnAG is unable to counteract TNF/IFN-induced atrophy (Fig. 25D), while they 
impair IL-6-mediated wasting (Fig. 25E). Accordingly, the ability of AG and UnAG to induce AktS473 
phosphorylation is blunted in TNF/IFN- but not in IL-6-treated C2C12 myotubes (Fig. 25F). 
Finally, by co-transfecting in C2C12 myoblasts pcDNA3-myc-p110 and pcDNA3-HA-p101 plasmids 
we observed an inhibition of the ability of ghrelin peptides to induce AktS473 phosphorylation, 
compared to empty vector (Fig. 25G). These data demonstrate that the upregulation of p101 
expression reduces AG and UnAG response. 
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Figure 25 (unpublished): The expression of p101 negatively affects ghrelin signaling. (A) Expression of p101 in C2C12 
myotubes upon treatment with 5 ng/ml or 10 ng/ml TNF/IFN combination, and with 20 ng/ml or 100 ng/ml IL-6. (B 
and C) C2C12 myotubes diameter was measured after 24- or 48-hour treatment with conditioned media obtained by 
supernatant of C26 (CCM) or LLC (LCM) cells. (D and E) Treatment with TNF/IFN (D), but not with IL-6 (E), blunts the 
anti-atrophic activity of AG and UnAG. (F) Phosphorylation of Akt
S473
, detected by Western blotting, upon 5-min 
treatment with 1 μM AG or UnAG, or 10 ng/ml IGF-1, in the presence or absence of 10 ng/ml TNF/IFN or 20 ng/ml 
IL-6. (G) Effect on protein levels of C2C12 myotubes transfection with empty vector (EV), pcDNA3-myc-p110 and 
pcDNA3-HA-p101 (p110 + p101), detected by Western blotting. (H) Phosphorylation of Akt
S473
, detected by Western 
blotting, upon 5-min treatment with 1 μM AG or UnAG, or 10 ng/ml IGF-1 in C2C12 myotubes transfected as in G. §P < 
0.05 vs. DM control; §§P < 0.01 vs. DM control; **P < 0.01 vs. CCM/LCM/IL-6 treatment. 
 
 
Catalytic inhibition of PI3K slightly improves cancer cachexia 
Based on our findings that inhibition of PI3K activity enhances AG/UnAG activity both in basal 
conditions and upon dexamethasone-treatment, and that the p101 expression inversely correlates 
with AG and UnAG response, we hypothesized that inhibition of PI3K may restore the GhrlR2 
response to the high levels of circulating ghrelin peptides. Indeed, accordingly to our hypothesis, 
PI3K inhibition should increase GhrlR2 density sufficiently to restore AG/UnAG activities. 
Therefore, we induced cancer cachexia injecting LLC cells in PI3KKD/KD mice, characterized by a 
kinase dead mutation in p110 [252]. Although PI3K is highly expressed in immune system cells 
[239], its catalytic inactivation do not affect circulating cytokines (data not shown) and tumor 
growth (Fig. 26A), in contrast to what observed in orthotopic growth of LLC [241]. We observed 
that the percentage of body weight and skeletal muscle mass loss in GAS, TA, and EDL is 
comparable between WT and (Fig. 26, B-E), and the atrogenes expression analysis confirms the 
data on muscle weight (Fig. 26, F and G). The frequency distribution of minimal Feret’s diameter of 
TA muscles show a shift of myofibers of PI3KKD/KD mice towards bigger diameters (Fig. 26H), as 
observed in Myh6/Ghrl mice (Fig. 20N). Nevertheless, food intake is improved in PI3KKD/KD mice at 
the last stages of cancer cachexia (Fig. 26I), indicating a global benefit induced by PI3K inhibition, 
as observed in Myh6/Ghrl mice (Fig. 20A). Importantly, we observed a delayed increase in 
circulating UnAG concentration in PI3KKD/KD mice, compared to WT (Fig. 26J), while circulating AG 
is comparable (Fig. 26K), suggesting that these mice have either a reduced negative energy 
balance, or a reduced UnAG-resistance, or both. However, the weak improvement of symptoms in 
tumor-bearing PI3KKD/KD mice reveals that the only PI3K inhibition is not sufficient to counteract 
or slow cancer cachexia. 
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Figure 26 (unpublished): The inhibition of PI3K slightly improves muscle wasting in cancer cachexia. (A-F) 
Comparison between WT and PI3K
KD/KD
 mice, at 24 days after LLC injection, of tumor weight (A), and percentage of 
body (B), gastrocnemius (C), tibialis anterior (D), and extensor digitorum longus (E) weight loss (N = 10 per group). In 
C-E percent reduction shown is between non-tumor-bearing and cachectic mice. (F and G) Atrogin-1 (Fbox32) and 
MuRF1 (Trim63) expression in tibialis anterior of non-tumor-bearing (CTR) and cachectic (CACHEXIA) mice. N = 5 (CTR) 
and 9 (CACHEXIA). (H) Frequency distribution of minimal Feret’s diameter of myofibers of cachectic mice, 
automatically quantified with ImageProPlus (N = 3 per group). (I-K) Daily food intake (I), and circulating UnAG (J) and 
AG (K) levels during cancer cachexia progression (N = 10 per group). *P < 0.05; **P < 0.01. 
 
PI3KKD/KD mice show skeletal muscle mass preservation in starvation but not in denervation 
Although we investigated the role of PI3K in the regulation of AG and UnAG response mainly in 
cancer cachexia models, we asked whether the induction of the expression of p101 instead p84/87 
could be a more general response to stress induced by different stimuli, as previously suggested in 
other systems [239]. Indeed, we observed that the p101/p84 expression ratio is induced in skeletal 
muscle during denervation, fasting, and after CTX injection (Fig. 27, A-C). Although in CTX-injected 
muscles we cannot rule out exactly the contribution of infiltrating inflammatory cells, basally 
expressing high level of PI3K, these results suggest that an increase in p101/p84 ratio may be a 
specific response of skeletal muscle to stress. However, PI3K inhibition do not affect skeletal 
muscle mass in denervation (Fig. 27, D and E). In contrast, muscular mass of PI3KKD/KD mice is 
preserved during fasting (Fig. 27, F and G), although body weight is unaffected (Fig. 27H). Although 
the explanation of these data needs further investigations, it was surprising to find an induction of 
p101/p84 ratio in skeletal muscle damaged by denervation or fasting, in which we demonstrated a 
protective activity of UnAG (Porporato 2013). However, based on our hypothesis, the reason could 
rely on the different fold-increase of p101/p84 ratio observed in denervation, fasting, and cancer 
cachexia models, negatively correlating with the ability of UnAG to maintain muscle mass, as 
shown in vitro.  
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Figure 27 (unpublished): PI3K
KD/KD
 mice are protected from fasting-induced skeletal muscle wasting. (A-C) Ratio 
between p101 and p84/87 expression comparing gastrocnemii of controlateral (CTRL) and denervated (DEN) mice 
after 7 days from sciatic nerve resection (A), gastrocnemii of fed and starved (STARV) mice after 48-hour of food 
deprivation (B), tibialis anterior of controlateral (CTRL), and CTX-injected (CTX) mice at 24h from inoculation (C). N = 4 
(Panel A) and N = 5 (Panel B and C). (D and E) Weight loss of gastrocnemius (D) and tibialis anterior (E) after 7 days 
from sciatic nerve resection. In D and E percent reduction shown is between denervated and unperturbed side. N = 10 
(WT) and 11 (PI3K
KD/KD
). (F-H) Effect of 48-hour of fasting. Weight loss of gastrocnemius (F) and tibialis anterior (G). 
(H) Body weight loss after 24- and 48-hour of food deprivation. In F and G percent reduction shown is between fasted 
and fed mice. N = 5 per group. *P < 0.05; **P < 0.01. 
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We demonstrated that AG and UnAG counteract skeletal muscle atrophy both in vitro, induced by 
glucocorticoids treatment, and in vivo, induced by either denervation or fasting (Porporato, 2013). 
Moreover, we provided the first genetic proof for the existence of a second ghrelin receptor 
distinct by GHSR-1a, herein referred as “GhrlR2”. Both AG and UnAG affect directly skeletal 
muscle, through GhrlR2 activation, without the involvement of the GHSR-1a/GH/IGF-1 axis 
(Porporato, 2013). Consistently, the anti-atrophic activity of AG and UnAG is distinct with that of 
IGF-1. Indeed, IGF-1 actions involve both mTORC1 and mTORC2 activation, depend on PI3K and 
do not require the activity of p38 (Porporato, 2013). Interestingly, the physiological role of ghrelin 
in the coordination of fasting and negative energy balance response is consistent with the inability 
of both AG and UnAG to induce protein synthesis and hypertrophy, a main feature of IGF-1 anti-
atrophic activity.  
Surprisingly, we observed that AG lacks anti-atrophic activity in WT mice, while it counteracts 
atrophy in Ghsr-/- mice. Conversely, UnAG treatment impairs  muscle wasting both in WT and in 
Ghsr-/- mice. Although we would have expected that GHSR-1a/GH/IGF-1 axis would contribute to 
AG, but not UnAG,  anti-atrophic activity, our finding indicates that not only GHSR-1a/GH/IGF-1  
axis does not contribute, but impairs the GhrlR2-mediated anti-atrophic activity. Thus, we may 
raise the hypothesis that, in vivo, AG treatment by activating GHSR-1a would result in the 
inhibition of GhrlR2 function. However, as GHSR-1a is not expressed in skeletal muscle [212], we 
need to postulate that such cross-regulation is not cell autonomous and would imply the release 
of a circulating factor from a GHSR-1a-expressing tissue acting on GhrlR2 in the skeletal muscle. 
Consistently, it has been recently shown that local administration of AG in the skeletal muscle 
improves insulin sensitivity [211], while systemic administration of AG is diabetogenic and impairs 
insulin sensitivity in skeletal muscle [210]. These findings support the hypothesis that a circulating 
factor mediates GHSR-1a and GhrlR2 cross-talk. Although this hypothesis has not proved yet, these 
findings underscore  the different biological significance of AG and UnAG, as indicated by the 
differences observed in body weight loss of starved mice treated with either AG or UnAG (Fig. 19). 
In addition,  ghrelin and GOAT genes are regulated by distinct transcriptional factors [151], and 
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circulating levels of AG and UnAG are differently affected during fasting [148], enforcing the 
concept that UnAG features physiological roles partially distinct from AG. Consistently, it has been 
reported that only UnAG promotes muscle regeneration upon ischemic damage, further 
supporting different roles of ghrelin peptides [195]. Although mice carrying ablation of either Ghrl, 
or Ghsr, or GOAT show no substantial differences in basal conditions compared to WT mice, 
studies of the response of these mice to either calorie restriction or high-fat diet revealed that 
ghrelin system is particularly relevant for glucose homeostasis and regulation of body weight [175, 
176]. Notably, the double knockout mice lacking both Ghrl and Ghsr genes show reduced body 
weight and increased energy expenditure also during a standard diet [270], suggesting that other 
components, still unidentified, are involved in the ghrelin system. However, the biological 
significance of the differences between AG and UnAG is still elusive.  
 A critical point undermining the understanding of AG and UnAG physiology is that the identity of  
GhrlR2 is still unknown. To address this issue, we are now testing a short list of candidate 
receptors obtained through two different approaches: i) we tested the ability of UnAG to recruit -
arrestin to the activated GPCR in a multiple screening covering the global portfolio of GPCRs 
developed by DiscoveRx Corporation; ii) on the other hand, in collaboration with Mauro Giacca at 
ICGEB in Trieste, we performed a high-throughput-screening (HTS) based on the loss of UnAG anti-
apoptotic activity upon transfection of a siRNA library of mouse GPCRs. The discovery of the 
identity of GhrlR2, and/or other receptors, will help our understanding of ghrelin peptides-
receptors interactions and regulation. 
The finding that both AG and UnAG impair skeletal muscle atrophy, acting directly on skeletal 
muscle independently of GHSR-1a activity, prompted us to investigate their ability to improve lean 
body mass in cancer cachexia. So far, there are no specific drugs counteracting cancer cachexia, in 
particular targeting skeletal muscle. Indeed, although the loss of skeletal muscle mass and 
function is the primary cause of death for respiratory failure in cancer patients [51], all the drugs 
used in clinical practice against cancer cachexia are based on the reduction of anorexia and 
inflammation. In fact, the two most utilized drugs for cancer cachexia are megestrol acetate, 
stimulating appetite, and glucocorticoids, inhibiting inflammation, but both of them are ineffective 
in the long term [50]. Interestingly, it has been recently concluded a phase III clinical trial assessing 
the efficacy of anamorelin, a GHSR-1a agonist, in counteracting cachexia in NSCLC patients. 
Although results have not been published yet, clinical data revealed an improvement in lean body 
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mass and body weight, but few benefits in muscle strength (ESMO 27/09/2014 Press Release: 
Anamorelin Shown to Improve Appetite and Body Mass in Patients with Cancer Anorexia-
Cachexia). Though the ability of anamorelin to activate GhrlR2 has not been proved yet, it is 
possible that this drug binds also to the novel receptor in the skeletal muscle, thus affecting cancer 
cachexia through multiple mechanisms. However, it is reasonable to assume that the efficacy of 
anamorelin resides on its GHSR-1a-mediated orexigenic, GH-releasing, and anti-inflammatory 
activities, and to a lesser extent on a direct anti-atrophic activity in skeletal muscle. In addition, 
our finding that AG treatment of WT mice fails to protect from denervation-induced muscle 
wasting, while it does protect in Ghsr-/- mice, indicating that its anti-atrophic activity is 
independent from anorexia and/or inflammation, lead us to doubt on the AG ability to directly 
affect skeletal muscle mass in physiological GHSR-1a-active systems. Moreover, AG-triggered 
GHSR-1a activation may be detrimental, as it leads to GH-dependent induction of IGF-1, which 
may enhance tumorigenesis [225], and it is diabetogenic by reducing insulin sensitivity [210]. For 
these reasons, UnAG, which does not bind to GHSR-1a, might be a promising novel approach for 
cancer cachexia. Surprisingly, UnAG featured a weak efficacy in counteracting cancer cachexia, 
suggesting that the GHSR-1a-mediated orexigenic, GH-releasing, and anti-inflammatory activities 
are indeed the key AG actions underlying its role as anti-cachectic treatment.  
However, the weak anti-cachectic efficacy of UnAG observed in LLC-bearing mice may depend on 
the deregulation of GhrlR2 signaling. Indeed, we demonstrated that GhrlR2 is bona fide a Gs-
coupled receptor like -ARs: both induce cAMP pathway, and activate PI3K and PI3K, which 
reciprocally regulate ligand-triggered signaling. When this fine reciprocal regulation is impaired, 
the consequence could be a pathologic modulation of agonist response. Indeed, as demonstrated 
for -ARs in heart failure [236], we showed that in cancer cachexia p101/p84 expression ratio 
increases in skeletal muscle. Moreover, we observed a negative correlation between p101 
expression and ghrelin response, both in vitro and in vivo. Our results support the hypothesis that 
the upregulation of p101, instead p84/87, leads, as previously described [236], to a diminished 
density of receptors regulated by this mechanism, including GhrlR2. We are currently addressing 
whether cachectic muscle features a reduced GhrlR2 density at the plasma membrane. 
Importantly, based on our findings about the ability of different cytokines to finely modulate p101 
expression, we can assume that in different genetic backgrounds, cancer types and stages, we will 
observe different UnAG responses, as suggested by results with conditioned media obtained by 
C26 and LLC cells. Hence, it is likely that in cachectic patients the modulation of PI3K subunits 
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expression may be not very linear as we found in LLC cachexia model. Indeed, microarray analysis 
of muscle biopsies from cachectic patients, did not reveal a clear modulation of p101 and p84/87 
expression compared to samples of non-cachectic patients [271]. However, the elucidation of the 
mechanisms affecting UnAG activity and receptor(s) regulation is crucial to increase our 
knowledge on cancer cachexia, to better design therapeutics, and to stratify cancer patients.  
Interestingly, during cachexia the concentration of circulating AG and total ghrelin is upregulated, 
independently from the underlying pathology [226-232]. Consistently, we showed that both 
circulating AG and UnAG are elevated in LLC-bearing mice, and that UnAG is also upregulated in 
C26 model. This increase may be due by either a compensatory mechanism, in response to 
reduced food intake and negative energy balance, or an impaired tissues response to ghrelin 
peptides, or both. The hypothesis of an AG resistance related to GHSR-1a has been already 
reported [233-235]. Since GHSR-1a is a highly complex receptor that can dimerize with several 
other receptors, modulating its signaling [128], the mechanism underlying its desensitization may 
be indirect, but there are no data about it. In contrast, here we showed a GhrlR2-associated 
resistance in cancer cachexia, due, at least in part, to a deregulation of PI3K. Consistently, we 
hypothesized that PI3K inhibition could restore, at least in the early stages of cancer cachexia, a 
physiologic ghrelin response and/or energy balance. However, we found that the only inhibition of 
PI3K weakly ameliorates cachexia symptoms, but, importantly, induces a delay in circulating 
UnAG upregulation, suggesting either an improvement in energy balance or in UnAG response. 
However, these data demonstrate that the postulated increase in the density of PI3K-regulated 
receptors, including GhrlR2, is not sufficient to significantly counteract cancer cachexia. Otherwise,  
another explanation may rely on a balanced upregulation of both positive and negative signaling 
regulating skeletal muscle mass. Indeed, since the internalization mediated by PI3K seems 
particularly related to Gs-coupled receptors, it has been recently demonstrated that PTH-related 
hormone, derived from tumor, promotes cancer cachexia [72], and its receptor is a Gs-coupled 
receptor [272], hence likely regulated by PI3K. However, it needs further investigations to 
address this issue.  
The demonstration that the inhibition of PI3K enhances AG and UnAG actions in both atrophic 
and basal C2C12 myotubes indicates the crucial role of signal strength. Indeed, cAMP signaling 
impairs atrophy and induces hypertrophy in skeletal muscle, as revealed by the ability of 2-AR 
agonists to counteract muscle wasting in several diseases [25]. In particular, it has been 
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demonstrated that 2-AR agonists improve skeletal muscle mass and functions in cancer cachexia 
[273-281]. In contrast, the inability of AG and UnAG to induce hypertrophy and to significantly 
affect skeletal muscle mass in cancer cachexia suggests that the cAMP signal strength is crucial to 
determine AG/UnAG activity on skeletal muscle mass. Indeed, a possible explanation may rely on 
the amount of receptors in the plasma membrane. In fact, GhrlR2 is expressed at very low 
abundance in cardiomyocytes and C2C12 myoblasts, as compared to 2-ARs [184, 189]. The ability 
of AG and UnAG to induce hypertrophy in vitro only in the presence of PI3K inhibitor suggests 
that the amount of cAMP signaling determines the balance between catabolic and anabolic 
functions, assuming that the inhibition of PI3K increases GhrlR2 density at the plasma membrane, 
thus enhancing cAMP signaling triggered by AG and UnAG. In addition to cAMP, another crucial 
second messenger likely involved in the balance between anti-atrophic/hypertrophic pathways is 
PIP3, produced by PI3Ks, although this issue needs further investigation. However, to evaluate in 
vivo if UnAG ability to counteract muscle wasting is improved when PI3K is inhibited, we 
generated Myh6/Ghrl X PI3KKD/KD mice, in which we will assess UnAG protective activity in models 
of cancer cachexia, denervation, and starvation. 
Interestingly, we showed that UnAG enhances satellite cells (SCs) ability to regenerate skeletal 
muscle and to maintain the stem cells pool (Reano and Angelino, unpublished). It is relevant to 
note that UnAG pharmacological treatment of Ghsr-/- mice upregulates the Wnt pathway in 
skeletal muscle (data from [282] analyzed with Panther - http://www.pantherdb.org/), which is 
crucial in the regulation of SCs and myofibers activities, supporting the concept of an active role of 
ghrelin peptides in muscle regeneration and mass regulation [26, 27, 283, 284]. AG and UnAG 
induce C2C12 myoblasts differentiation and fusion into multinucleated myotubes, through 
activation of p38 [189]. Since p38 is a multi-functional protein, orchestrating different pathway in 
different conditions [265], it is likely that the ability of ghrelin peptides to induce p38 activation in 
both myoblasts [189] and myotubes (Porporato 2013) could explain the apparent conflict about 
the UnAG ability to promote both SCs self-renewal and differentiation. The UnAG unique feature 
to stimulate the whole SCs-driven repair of damaged skeletal muscle is particular relevant in a 
cancer cachexia context. Indeed, although the contribution of SCs in the context of skeletal muscle 
atrophy is poorly understood, it has been demonstrated that in cancer cachexia the regenerative 
process is deregulated and impaired [57-61]. In particular, although SCs are activated during 
cancer cachexia, they fail to differentiate into mature myotubes, due by a persistent upregulation 
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of Pax7 induced by a serum factor(s) still unknown. On one hand, this evidence supports that the 
high levels of circulating ghrelin peptides do not improve neither muscle mass nor SCs functions. 
However, on the other hand, it suggests further investigation on the perspective to enhance UnAG 
signaling in cachexia by inhibition of PI3K. Although we have not still checked, in our models, SCs 
function and muscle regeneration, we hypothesize that cachectic Myh6/Ghrl mice will show an 
impairment in skeletal muscle regeneration process, despite the high concentration of circulating 
UnAG, and that cachectic PI3KKD/KD mice will show a partial restoration in SCs activities, likely 
affecting also other pro-regenerative factors, including, among others, Wnt-Fzd pathway. Indeed, 
beyond the UnAG ability to stimulate Wnt pathway, it is likely that, in both SCs and post-mitotic 
cells, the non-canonical Wnt pathway itself, mediated by a Gs-coupled signaling [26, 285], may be 
directly affected by PI3K inhibition. Nevertheless, we believe that only the combination of UnAG 
treatment with PI3K inhibition will significantly affect regeneration process in cancer cachexia.  
Although the serum factor(s) impairing regenerative process in cancer cachexia is still elusive [61], 
it has been shown that TNF stimulates myogenesis at low concentration (0.05 ng/ml), but, at 
higher concentration (from 0.5 to 100 ng/ml), TNF impairs myogenesis [57, 74, 89], suggesting 
that elevated doses of TNF, or prolonged exposure to it, lead to a deregulation of regenerative 
process. Consistently, it has been shown that long-treatment with TNF induces a biphasic 
activation of NF-kB, and the second (and persistent) activation results in skeletal muscle decay 
[88]. Since we demonstrated that p101 is specifically affected by TNF in a dose-dependent 
manner, we hypothesize that AG and UnAG response through GhrlR2, should be inversely 
correlated to TNF concentration. In fact, it has been demonstrated that UnAG inhibits NF-kB 
activation triggered by 5 ng/ml TNF/IFN treatment [222], but we showed that UnAG is totally 
ineffective to impair muscle wasting induced by 10 ng/ml TNF/IFN, inversely reflecting p101 
expression. These evidences point out the great relevance of chronic inflammation in regulating 
tissue pathways, and tissue response to several factors. Since several pathologies are associated 
with a persistent inflammatory state, such as cancer cachexia, muscle dystrophy, and aging, the 
study of molecular adaptation to chronic inflammation has strong translational perspectives.  
Based on these data, the elevation of ghrelin peptides in cancer cachexia seems rely on a 
compensation to a ghrelin resistance, through both GHSR-1a and GhrlR2. However, it is likely that 
other mechanisms contribute to the upregulation of circulating AG and UnAG. Indeed, it may be a 
consequence of alterations in metabolic, neural, and endocrine pathways, induced as a 
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physiological response to maintain homeostasis during cancer cachexia. Indeed, several stressors 
induce changes in the circulating concentration of both AG and UnAG [286]: on one hand, physical 
stressors, such as exercise, abdominal surgery and endotoxin injection, decrease circulating AG 
and UnAG concentration; on the other hand, metabolic and psychological inducers of stress, such 
as caloric restriction, acute fasting, and cold exposure, increase plasma ghrelin peptides [286]. The 
release of ghrelin peptides from the stomach is the result of multiple simultaneous signals, coming 
from neural, endocrine, and metabolic systems, as elucidated by the identification of a repertoire 
of GPCRs regulating ghrelin release [287]. Since it has been recently reported that in cancer 
cachexia the autonomic nervous system, in particular the sympathetic branch, appears 
deregulated [115, 116], the increase in plasma ghrelin peptides may reflect this alterations. 
Indeed, both cholinergic and adrenergic agonists induce ghrelin release from stomach, indicating 
that the control of circulating ghrelin levels is regulated by both vagal and sympathetic systems 
[171, 194, 288-290]. Moreover, AG treatment increases muscle sympathetic activity in 
unperturbed conditions, while AG strongly inhibits it during experimental stress [291], suggesting 
a fine cross-talk between ghrelin and autonomic nervous system. Hence, circulating ghrelin in 
cancer cachexia may be, at least in part, the result of stress-related activation/deregulation of the 
autonomic nervous system, being the main player to maintain homeostasis during stress [292]. 
Moreover, it has been demonstrated that mTOR activity in the stomach regulates the expression 
of both ghrelin and GOAT [293]. Since mTOR is activated by positive energy balance, being a 
sensor of intracellular ATP/AMP ratio [294], it is likely that also this mechanism may be involved in 
the increase of circulating ghrelin peptides in cancer cachexia. Indeed, the nutritional state is a 
potent regulator of plasma ghrelin peptides concentration, reciprocally affected by positive and 
negative energy balance [295], and, in turn, ghrelin is involved in the adaptive response to weight 
loss [296]. Finally, although the role of insulin in the regulation of circulating ghrelin peptides is not 
completely understood [165-171], it is likely that the insulin resistance, associated with cancer 
cachexia [118, 119, 297], contributes to the elevation of plasma ghrelin. In conclusion, all of these 
physiological responses to cancer, alone or together with the adaptation to ghrelin resistance, may 
lead to the increase in circulating ghrelin peptides observed in cancer cachexia, and further 
investigations are needed to assess this issue. 
Finally, although tumor-bearing PI3KKD/KD mice showed weak improvements compared to WT, the 
inhibition of PI3K preserves skeletal muscle mass during fasting. Indeed, after 48-hour of food 
deprivation PI3KKD/KD mice present a significantly reduction of muscle weight loss than WT mice, 
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while after 7 days from sciatic denervation the are no significant differences in muscle mass 
between PI3KKD/KD and WT mice. These findings point out the importance of a systemic response, 
as in fasting, in the regulation of PI3K. Although these data need further investigations, we can 
speculate that the reduction of skeletal muscle atrophy observed in starved PI3KKD/KD mice may 
be due by an increase of beneficial signaling mediated by Gs-coupled receptors, directly in 
skeletal muscle or in other tissues affecting skeletal muscle.  
In conclusion, these data demonstrate that AG and UnAG counteract skeletal muscle atrophy 
acting directly in skeletal muscle through a still unknown receptor, GhrlR2. Moreover, we showed 
that cancer cachexia may be associated with a ghrelin resistance related not only to GHSR-1a, but 
also to the novel GhrlR2. The mechanism of the reduced ghrelin response through the GhrlR2 
seems to rely on an upregulation of PI3K, likely leading to a massive internalization of GhrlR2, 
thus decreasing responsiveness to ghrelin peptides. Finally, we demonstrated that the only 
inhibition of PI3K in cancer cachexia does not strongly affect lean body mass, but, in contrast, 
preserves skeletal muscle in fasting. These findings improve our knowledge on ghrelin and PI3K 
physiology, regulating skeletal muscle mass in both physiological and pathological conditions. 
 
The main forthcoming investigations will be the identification of GhrlR2 receptor, and therefore 
the evaluation of its expression and regulation in physiological and pathological conditions. The 
discovery of GhrlR2 receptor will allow not only to better characterize both the ghrelin resistance 
observed in cancer cachexia and its functions in other physiological systems, but also to design 
agonists that will have relevant therapeutic implications. Moreover, we will assess if the 
simultaneous upregulation of UnAG and inhibition of PI3K, obtained either in Myh6/Ghrl X 
PI3KKD/KD mice or by treating Myh6/Ghrl mice with AS605240, as reported [236], improve muscle 
mass and regenerative potential in cancer cachexia, as well as in denervation and in fasting. 
Finally, we will evaluate the role of inflammation and other stress in the regulation of PI3K 
activity in skeletal muscle, and, in turn, we will assess if the increase of p101 expression leads to a 
downregulation of GhrlR2 density at plasma membrane, thus affecting ghrelin response. Besides 
the relevance of these investigations to increase our knowledge on the molecular mechanisms 
underlying cancer cachexia progression, and ghrelin and PI3K physiology, the results obtained will 
have strong therapeutic and translational implications.   
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Cachexia is a wasting syndrome associated with cancer, AIDS, multiple sclerosis, and several other disease 
states. It is characterized by weight loss, fatigue, loss of appetite, and skeletal muscle atrophy and is associ-
ated with poor patient prognosis, making it an important treatment target. Ghrelin is a peptide hormone that 
stimulates growth hormone (GH) release and positive energy balance through binding to the receptor GHSR-1a. 
Only acylated ghrelin (AG), but not the unacylated form (UnAG), can bind GHSR-1a; however, UnAG and AG 
share several GHSR-1a–independent biological activities. Here we investigated whether UnAG and AG could 
protect against skeletal muscle atrophy in a GHSR-1a–independent manner. We found that both AG and UnAG 
inhibited dexamethasone-induced skeletal muscle atrophy and atrogene expression through PI3Kβ-, mTORC2-, 
and p38-mediated pathways in myotubes. Upregulation of circulating UnAG in mice impaired skeletal muscle 
atrophy induced by either fasting or denervation without stimulating muscle hypertrophy and GHSR-1a–medi-
ated activation of the GH/IGF-1 axis. In Ghsr-deficient mice, both AG and UnAG induced phosphorylation of 
Akt in skeletal muscle and impaired fasting-induced atrophy. These results demonstrate that AG and UnAG act 
on a common, unidentified receptor to block skeletal muscle atrophy in a GH-independent manner.
Introduction
Skeletal muscle atrophy involves massive loss of muscle structural 
proteins, which leads to muscle weight decrease and progressive 
loss of muscle function. Skeletal muscle atrophy is induced by 
muscle denervation and disuse, and it is also the key component 
of cachexia, a catabolic, debilitating response to several diseases. 
Cachectic patients not only sustain a decreased quality of life, but 
also face a worse prognosis of the underlying pathology, making 
cachexia an important target for treatment (1). Ghrelin is a circu-
lating peptide hormone, octanoylated on Ser3, that is mainly pro-
duced by the stomach, which, by acting on the hypothalamus and 
the pituitary, induces GH secretion and stimulates food intake and 
adiposity through binding to its receptor, GHSR-1a (2–5). In addi-
tion to its endocrine activities, ghrelin protects cardiac function 
after heart damage (6, 7). In vitro, ghrelin inhibits the apoptosis 
of cardiomyocytes and other cell types by activating PI3K/Akt and 
ERK-1/2 pathways (8–10). Acylated ghrelin (AG) and unacylated 
ghrelin (UnAG) are generated from the same precursor, which can 
be acylated by the specific intracellular ghrelin-O-acyltransferase 
GOAT (11, 12). UnAG, which is far more abundant in plasma than 
AG, does not bind to GHSR-1a, lacks any GH-releasing activity 
(13), and has been considered for many years to be the inactive 
product of ghrelin catabolism. However, UnAG shares with AG 
common high-affinity binding sites on several cell types lacking 
GHSR-1a, including myocardial and skeletal myocytes, where they 
stimulate survival and differentiation, respectively (8, 9, 14–16). 
Furthermore, UnAG regulates gene expression in fat, muscle, and 
liver independently of GHSR-1a (17).
In both human patients and experimental models, AG ameliorates 
cachexia induced by several pathological conditions (6, 7, 13, 18–21). 
Although AG may inhibit cachexia by stimulating food intake, posi-
tive energy balance, and release of GH and IGF-1, the mechanisms 
underlying its anticachectic activity have not been fully elucidated.
Since we have previously shown that AG and UnAG, indepen-
dently of GHSR-1a, inhibit apoptosis of cardiomyocytes by acti-
vating PI3K/Akt (8), a major antiatrophic signaling pathway (22, 
23), and stimulate C2C12 skeletal myoblast differentiation (16), 
we investigated whether AG and UnAG could protect skeletal mus-
cle from atrophy. Here, we provided evidence in vitro and in vivo 
that AG and UnAG, independently of GHSR-1a and activation of 
the GH/IGF-1 axis, trigger an antiatrophic signaling pathway by 
acting directly on the skeletal muscle, thereby protecting it from 
experimentally induced atrophy.
Results
AG and UnAG prevent dexamethasone-induced atrophy in C2C12-derived 
myotubes via mTORC2. C2C12 myotubes are a widely used model to 
study in vitro skeletal muscle atrophy induced by the synthetic glu-
cocorticoid dexamethasone (24–26). Muscle atrophy was measured 
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both as reduction of myotube diameter and as expression of the 
muscle-specific ubiquitin ligases Atrogin-1 (also known as MAFbx) 
and MuRF1, which drive muscle protein degradation in several 
models of muscle atrophy (24–27). Myotubes were treated with 
1 μM dexamethasone for 24 hours in the presence or absence of 
10 nM AG or UnAG, or with 10 ng/ml IGF-1 as a positive control of 
atrophy protection. Treatment with dexamethasone reduced myo-
tube diameters by 20% and induced Atrogin-1 and MuRF1 expres-
sion. AG and UnAG impaired both these effects (Figure 1, A–C).
Skeletal muscle atrophy and atrogene expression can be opposed 
by the activation of mammalian target of rapamycin (mTOR), which, 
by forming 2 distinct protein complexes, mTORC1 and mTORC2, 
triggers distinct pathways that lead, respectively, to increased pro-
tein synthesis and to inhibited protein degradation (28, 29). To assess 
whether mTOR mediates the signaling triggered by AG/UnAG, myo-
tubes were incubated with rapamycin, an inhibitor of mTORC1, 
which, upon prolonged treatment, also impairs the assembly of 
mTORC2 in several cell types, including C2C12 cells (refs. 30–32 
and Supplemental Figure 1, A and B; supplemental material avail-
able online with this article; doi:10.1172/JCI39920DS1).
Upon 24-hour treatment of atrophying myotubes with 20 ng/
ml rapamycin, the antiatrophic activity of AG/UnAG on myotube 
diameter was fully reverted (Figure 1D), which indicates that acti-
vation of mTOR is indeed required for the antiatrophic activity of 
AG and UnAG. Moreover, in the same assay, the antiatrophic activ-
ity of AG/UnAG was inhibited by 100 nM wortmannin, an inhibi-
tor of PI3K, whose product PI(3,4,5)P3 is essential for the activity 
of Akt, a substrate of mTORC2 that also mediates the activation 
of mTORC1 (29). These findings indicate that AG/UnAG antiat-
rophic activity requires both mTOR and Akt. Thus, we assayed the 
activity of both mTOR complexes. We evaluated mTORC2 activ-
ity as phosphorylation of AktS473, which, in turn, phosphorylates 
FoxO3aT32, thus preventing Atrogin-1 transcription (24, 25). AG/
UnAG, as well as IGF-1, induced phosphorylation of AktS473 and 
FoxO3aT32 (Figure 1, E and F), which indicates that they activate 
mTORC2-mediated pathways.
The activity of mTORC1 was assayed as phosphorylation of 
S6KT389, a direct substrate of mTORC1, and of its substrate 
S6S235/236, a ribosomal protein whose phosphorylation mediates 
protein synthesis (29). AG and UnAG did not induce phosphory-
lation of S6KT389 and S6S235/236 (Figure 1, G and H), nor protein 
synthesis (as measured by [3H]-leucine incorporation; Figure 1I) 
or myotube hypertrophy (Figure 1A). Conversely, IGF-1 induced 
S6KT389 and S6S235/236 phosphorylation, [3H]-leucine incorpora-
tion, and myotube diameter increase, as expected.
By silencing raptor and rictor, specific components of mTORC1 
and mTORC2, respectively (Figure 1J), we observed that down-
regulation of rictor abrogated the protective effect of both pep-
tides on dexamethasone-induced muscle atrophy, measured as 
myotube diameter, while it did not affect the antiatrophic activ-
ity of IGF-1 (Figure 1K). Conversely, raptor silencing impaired 
IGF-1 antiatrophic activity without affecting that of AG/UnAG. 
These results indicate that mTORC2 pathway mediates AG/
UnAG antiatrophic activity in C2C12 myotubes, without involv-
ing mTORC1-mediated protein synthesis.
To identify the signaling pathways differently activated by AG/
UnAG and IGF-1, we investigated the role of p38 serine kinase, 
whose activation by AG/UnAG mediates C2C12 myoblast differ-
entiation (16). In C2C12 myotubes, AG/UnAG, as well as IGF-1, 
induced phosphorylation of p38T180/Y182 (Figure 2A), and its phar-
macological inhibition impaired the antiatrophic activity of AG/
UnAG, but not of IGF-1 (Figure 2B).
Activation of p38 has been reported to downregulate Atrogin-1, 
thereby contributing to the protection of skeletal muscle from 
atrophy (33). On the other hand, p38 mediates induction of Atro-
gin-1 by TNF-α and oxidative stress and of MuRF1 by serum star-
vation (34–37). Inhibition of p38 with SB203580 reduced dexa-
methasone-induced expression of both Atrogin-1 and MuRF1; 
nevertheless, induction of Atrogin-1, but not MuRF1, was still 
significant (Figure 2, C and D). In the presence of SB203580, AG 
and UnAG, but not IGF-1, failed to further reduce the residual 
induction of Atrogin-1, which indicates that p38 mediates AG/
UnAG signaling in regulating Atrogin-1 expression.
To further characterize AG/UnAG antiatrophic activity, we 
treated C2C12 myotubes with NF449, a compound uncoupling 
Gαs from GPCRs, which inhibits antiapoptotic activity of AG and 
UnAG in pancreatic β cells (9, 38). NF449 completely abrogated 
AktS473 phosphorylation and antiatrophic activity of AG/UnAG 
without affecting IGF-1 activities (Figure 2, E and F), which sup-
ports the hypothesis that AG and UnAG act through a GPCR, as 
previously suggested (9).
PI3K α and β isoforms mediate Akt activation upon stimulation 
of tyrosine kinase receptors and GPCRs, respectively (39, 40). We 
dissected the contribution of PI3Kα and PI3Kβ to IGF-1 and AG/
UnAG antiatrophic activity using isoform-specific PI3K inhibitors. 
Whereas inhibition of PI3Kα by PIK-75 abolished IGF-1 antiat-
rophic activity, it did not affect AG/UnAG protection. Conversely, 
inhibition of PI3Kβ by TGX-221 impaired AG/UnAG antiatrophic 
activity while not affecting IGF-1 protection (Figure 2G). The 
involvement of PI3Kβ in AG/UnAG antiatrophic activity was fur-
ther supported by the finding that TGX-221 prevented AG/UnAG 
from reducing dexamethasone-induced Atrogin-1 expression (Fig-
ure 2H). Together, these data strongly suggest that AG/UnAG acts 
through GPCR-dependent signaling pathways involving a PI3K 
isoform distinct from that of IGF-1.
Glucocorticoids induce muscle mass reduction by also upregu-
lating the expression of myostatin, a TGF-β family member that 
acts as a negative regulator of muscle mass. Myostatin reduces the 
Figure 1
AG and UnAG protect C2C12 myotubes from dexamethasone-induced 
atrophy without induction of protein synthesis or hypertrophy. (A) Myo-
tube diameters were measured after 24-hour treatment in differentia-
tion medium (DM) with 10 nM AG, 10 nM UnAG, and/or 1 μM dexa-
methasone (DEXA). In every experiment, 10 ng/ml IGF-1 was used as 
positive control for antiatrophic/hypertrophic activity. (B and C) Atro-
gin-1 and MuRF1 expression analysis upon dexamethasone treatment 
with or without AG and UnAG. (D) Treatment with 100 nM wortman-
nin (W) or 20 ng/ml rapamycin (R) reverted the antiatrophic activity of 
AG and UnAG on myotube diameter. Control myotubes in differentia-
tion medium were treated with DMSO, a vehicle for both wortmannin 
and rapamycin. (E and F) Phosphorylation of AktS473 and FoxO3aT32, 
detected by Western blotting, upon treatment for 20 minutes with 1 μM 
AG or UnAG. Shown are representative blots and quantification of 3 
independent experiments. (G–I) IGF-1, but not AG and UnAG, induced 
protein synthesis, as determined by phosphorylation of S6KT389 (G) or 
S6S235/236 (H) and by incorporation of [3H]-leucine (I). (J) Effect of raptor 
and rictor silencing on protein levels, detected by Western blotting. (K) 
Silencing of rictor, but not of raptor, reverted the antiatrophic activity of 
AG and UnAG on the diameter of myotubes treated as in A. #P < 0.05, 
§P < 0.01 vs. DM control; *P < 0.01 vs. DEXA treatment.
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size of human skeletal muscle cell–derived myotubes by reducing 
mTOR/Akt/p70S6K signaling, while simultaneous treatment with 
IGF-1 restores myotube size, Akt phosphorylation, and protein 
synthesis (41, 42). In C2C12 myotubes, dexamethasone treatment 
actually induced the expression of myostatin, which was signifi-
cantly reduced by IGF-1. However, AG/UnAG had no effect on 
myostatin expression (Supplemental Figure 1C), providing further 
evidence that ghrelin and IGF-1 inhibit muscle atrophy through 
distinct, partially overlapping, mechanisms.
Tg mice with high levels of circulating UnAG are protected from fasting- 
and denervation-induced atrophy. To verify in vivo the relevance of the 
findings described above, we used a strain of Tg mice with cardiac-
specific ghrelin gene (Ghrl) expression. In these mice (referred to 
herein as Myh6/Ghrl), Ghrl overexpression in the heart results in 
Figure 2
AG and UnAG antiatrophic signaling 
is mediated by p38 and acts through a 
GPCR-dependent signaling pathway 
involving PI3Kβ. (A) Phosphorylation of 
p38T180/Y182, detected by Western blot-
ting, after 20-minute treatment with 1 μM 
AG or UnAG. Shown are representative 
blots and quantification of 3 independent 
experiments. (B) Treatment with the p38 
inhibitor SB203580 (5 μM) reverted the 
antiatrophic activity of AG and UnAG on 
myotube diameter upon treatment with 
dexamethasone. (C and D) Atrogin-1 and 
MuRF1 expression analysis upon dexa-
methasone treatment with or without AG 
and UnAG in the presence or absence 
of 5 μM SB203580. (E) AG and UnAG 
phosphorylation of AktS473 was abolished 
upon treatment with 10 μM NF449, a Gαs 
subunit–selective G protein antagonist. 
Shown are representative blots and quan-
tification of 3 independent experiments. 
(F) Treatment with 10 μM NF449 reverted 
the antiatrophic activity of AG and UnAG 
on myotube diameter upon dexametha-
sone treatment. (G) Treatment with 25 
nM PIK-75, an inhibitor of PI3Kα, abol-
ished the antiatrophic effect of IGF-1 on 
myotube diameter upon dexamethasone 
treatment, without affecting AG and UnAG 
activity. The antiatrophic effect was abro-
gated by treatment with 200 nM TGX-221, 
an inhibitor of PI3Kβ. (H) Atrogin-1 expres-
sion analysis upon dexamethasone treat-
ment with AG, UnAG, and IGF-1 in the 
presence or absence of 200 nM TGX-221. 
In experiments with SB203580, NF449, 
PIK-75, and TGX-221, control myotubes 
in differentiation medium were treated with 
DMSO, a vehicle for all these compounds. 
#P < 0.05, §P < 0.01 vs. DM control; 
*P < 0.05, **P < 0.01 vs. DEXA treatment.
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a 50-fold increase of circulating UnAG, without affecting AG lev-
els (Table 1), as previously observed in other Ghrl-overexpressing 
Tg mice (43–45). Ghrl mRNA overexpression was restricted to the 
myocardium of Myh6/Ghrl mice, without leakage in the skeletal 
muscle (Supplemental Figure 2A). Moreover, consistent with the 
inability of UnAG to activate GHSR-1a and to promote GH release 
and adiposity, Myh6/Ghrl mice did not feature any change in cir-
culating IGF-1 concentration, tibial and nasoanal length, BMI, 
or food intake compared with their WT littermates. In addition, 
fasting decreased IGF-1 and increased ghrelin circulating concen-
trations to the same extent in WT and Myh6/Ghrl mice (Table 1). 
These data strongly indicate that the upregulation of circulating 
UnAG in Myh6/Ghrl mice does not activate GHSR-1a in the pitu-
itary and hypothalamus, stimulate the GH/IGF-1 axis, or affect 
endogenous ghrelin regulation. Moreover, tissue expression of 
IGF-1, which in skeletal muscle may act locally in a paracrine/
autocrine manner (46), was not altered in Myh6/Ghrl mice, either 
in fed or in fasted animals (Supplemental Figure 2B).
Although AG and UnAG differently regulate insulin release and 
sensitivity (47), basal insulin level, glucose uptake, and insulin sen-
sitivity were not affected in Myh6/Ghrl mice (Table 1 and Supple-
mental Figure 2, C and D).
Notably, compared with WT animals, fed Myh6/Ghrl mice did not 
feature any difference in heart and gastrocnemius muscle weight 
(Table 1), fiber cross-sectional area (CSA) distribution, or hindlimb 
force (as measured by grasping test; Supplemental Figure 2, E and F), 
which indicates that high levels of circulating UnAG do not induce 
skeletal muscle hypertrophy in vivo, consistent with the inability of 
UnAG to induce hypertrophy in C2C12-derived myotubes.
To investigate whether UnAG might protect 
from muscle wasting, we induced skeletal muscle 
atrophy by food deprivation. After 48 hours of 
fasting, gastrocnemius weight was decreased by 
approximately 14% in WT mice, and by approxi-
mately 9% in Myh6/Ghrl mice, compared with 
fed animals (Figure 3A), which indicates that 
increased circulating UnAG results in 30% protec-
tion from fasting-induced loss in gastrocnemius 
mass. Accordingly, gastrocnemii CSA was reduced 
by 29% in WT mice and by 19% in Myh6/Ghrl mice 
compared with fed animals (Figure 3B), indicative 
of 34% protection. Similarly, extensor digitorum 
longus (EDL) muscle weight and mean fiber area 
of Myh6/Ghrl mice was reduced to a lesser extent 
than in WT animals (Figure 3, D and E). This pro-
tection was reflected by shift in CSA distributions 
of gastrocnemii and EDL — toward fibers with 
wider area — in Myh6/Ghrl compared with WT 
mice under fasting conditions (Figure 3, C and F).
After 48 hours of fasting, Atrogin-1 and MuRF1 
expression in gastrocnemii of WT animals dra-
matically increased. In Myh6/Ghrl mice, the 
induction of Atrogin-1 was significantly reduced 
by one-third, while MuRF1 was only slightly, not 
significantly, decreased (Figure 3, G and H).
Plasma levels of glycerol and FFAs did not 
change in fasted Myh6/Ghrl and WT mice (Sup-
plemental Figure 2, G and H), which indicates 
that fasting did not significantly affect either 
glycerol or FFA concentrations, consistent with 
previous reports in the FVB mouse background (48, 49). Moreover, 
hepatic phosphoenolpyruvate carboxykinase (PEPCK) expression 
was induced to the same extent in fasted Myh6/Ghrl and WT lit-
termates (Supplemental Figure 2I). Together, these data suggest 
that muscle wasting–resistant properties of Myh6/Ghrl mice do not 
depend on effects of UnAG on energy balance.
Furthermore, Myh6/Ghrl mice were protected from denervation-
induced muscle atrophy, an experimental procedure that does not 
affect animal daily food intake (Table 1). At 7 and 14 days after 
denervation, gastrocnemii weight of WT animals was reduced by 
21% and 27%, respectively, while the loss of muscle weight in Myh6/
Ghrl animals was significantly lower (Figure 4A). Consistently, gas-
trocnemii mean fiber CSA of WT animals was remarkably reduced 
at both 7 and 14 days after denervation, whereas CSA in Myh6/Ghrl 
animals was reduced to a lesser extent (Figure 4B). At 7 days after 
denervation, Myh6/Ghrl mice featured a mild shift of gastrocnemii 
CSA distribution that became impressive after 14 days (Figure 4, C 
and D). A strong inhibition of atrophy at 7 days after denervation 
was also evident in EDL (Figure 4, E and F) and tibialis anterior 
(TA) muscles (Figure 4, G and H).
Moreover, in gastrocnemii of Myh6/Ghrl mice, the induction of 
Atrogin-1 was reduced by 40% (Figure 4I). Conversely, MuRF1 was 
only slightly, not significantly, reduced (Figure 4J), consistent with 
the fasting-induced atrophy data. Together, these observations 
indicated that constitutive high levels of UnAG impair experimen-
tally induced atrophy in vivo, likely through a mechanism inde-
pendent of GHSR-1a and activation of the GH/IGF-1 axis.
UnAG pharmacological treatment induces antiatrophic signaling in 
muscle and inhibits fasting- and denervation-induced atrophy. Acute 
Table 1
Phenotypical characterization of Myh6/Ghrl mice
 WT Myh6/Ghrl
UnAG (pg/ml) 445.4 ± 155 25,000.5 ± 360A
AG, fed (pg/ml) 41.7 ± 1.6 39.3 ± 1.5
AG, fasted (pg/ml) 75.7 ± 8.8 68.2 ± 9.5
IGF-1, fed (ng/ml) 748.5 ± 56 765.5 ± 120
IGF-1, fasted (ng/ml) 398 ± 93 328 ± 37
Insulin (pg/ml) 571 ± 58 631 ± 129
Tibial length (mm) 19.65 ± 0.11 19.62 ± 0.22
Nasoanal length (mm) 91.59 ± 0.51 90.61 ± 0.95
BMI, fed (g/cm2) 3.32 ± 0.12 3.33 ± 0.08
BMI, fasted (g/cm2) 2.93 ± 0.06 2.92 ± 0.09
Gastrocnemius weight, fed (mg) 134.86 ± 4.6 137.2 ± 5.62
Gastrocnemius weight, fasted (mg) 118 ± 4 124 ± 3.1
Gastrocnemius weight/tibial length, fed (mg/mm) 6.86 ± 0.22 6.99 ± 0.25
Gastrocnemius weight/tibial length, fasted (mg/mm) 5.89 ± 0.14 6.36 ± 0.15B
Heart weight, fed (mg) 117.5 ± 11.8 122 ± 6.8
Heart weight, fasted (mg) 103.0 ± 7.1 105 ± 3.3
Heart weight/nasoanal length, fed (mg/mm) 1.22 ± 0.12 1.28 ± 0.08
Heart weight/nasoanal length, fasted (mg/mm) 1.16 ± 0.07 1.16 ± 0.03
Daily food intake (g) 4.66 ± 0.17 4.73 ± 0.07
Daily food intake, denervated (g) 4.60 ± 0.17 4.60 ± 0.18
Measurements were performed as described in Methods. Muscle mass and tibial length 
were calculated as the mean of right and left hindlimbs. n = 7 per group (fed); 4 per group 
(fasted 48 hours); 5 per group (denervated). Data are mean ± SEM. AP < 0.01 vs. WT.  
BP < 0.05 vs. WT.
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administration of exogenous UnAG at 100 μg/kg, a dose previ-
ously used for in vivo studies (6), induced phosphorylation of 
AktS473, FoxO3aT32, and p38T180/Y182 in WT gastrocnemii (Figure 5, 
A–C), which indicates that, in vivo, UnAG activates the same antia-
trophic signaling pathway as it does in C2C12 myotubes.
Repeated administration (every 12 hours) of UnAG protected 
mice from skeletal muscle atrophy induced by either fasting or 
denervation (Figure 5, D–I). UnAG treatment preserved gastroc-
nemii from weight and mean fiber CSA loss (Figure 5, D and E). 
Accordingly, frequency distribution of gastrocnemii CSA of fasted 
mice injected with UnAG showed a dramatic shift toward bigger 
fiber areas compared with saline-injected mice (Figure 5F).
Similarly, UnAG treatment of denervated mice resulted in a 25% 
protection from gastrocnemius weight loss and a significantly 
lower decrease of mean fiber CSA, although the CSA distribution 
of UnAG-injected mice showed only a very mild shift compared 
with saline-injected animals (Figure 5, G–I). Although the plasma 
concentration of UnAG after injection dropped to basal levels 
in about 2–4 hours (Supplemental Figure 3A), these data indi-
cate that repeated acute stimulation is sufficient to protect from 
experimentally induced skeletal muscle atrophy without affecting 
muscular IGF-1 expression (Supplemental Figure 3B).
AG and UnAG induce antiatrophic 
signaling and impair muscle atro-
phy in Ghsr–/– mice. The findings 
reported above, along with pre-
vious data on common binding 
sites for AG/UnAG in C2C12 
lacking Ghsr (16), strongly sug-
gest that AG and UnAG stimulate 
antiatrophic signaling in skeletal 
muscle through activation of a 
receptor distinct from GHSR-
1a. To verify this hypothesis, we 
assayed AG/UnAG antiatrophic 
signaling and activity in Ghsr–/– 
mice, in which AG fails to activate 
the GH/IGF-1a axis or stimulate 
appetite (50). Injection of either 
AG or UnAG induced AktS473 
phosphorylation in gastrocnemii 
of Ghsr–/– mice (Figure 6A). Con-
sistently, treatment of Ghsr–/– 
mice with 100 μg/kg AG or UnAG 
twice daily reduced gastrocnemii 
weight loss induced by 48-hour 
fasting by 30% compared with 
saline-treated animals (Figure 
6B). Moreover, the mean CSA loss 
of AG- and UnAG-injected mice 
strongly decreased compared with 
saline-injected animals, and CSA 
distribution shifted toward bigger 
areas (Figure 6, C and D).
In summary, these findings 
demonstrated that both AG and 
UnAG activate a direct antia-
trophic signaling pathway in 
skeletal muscle and protect from 
experimentally induced muscle 
atrophy, independently of the AG receptor GHSR-1a.
Discussion
Several studies have shown that AG protects from cachexia and 
prevents muscle proteolysis in vivo, supposedly through stim-
ulation of appetite and activation of the GH/IGF-1 axis medi-
ated by AG binding to GHSR-1a (6, 7, 18–21). However, here we 
provided in vitro and in vivo evidence that AG and UnAG exert 
antiatrophic activity by acting directly on the skeletal muscle, 
even in Ghsr–/– mice.
Upregulation of circulating UnAG, which does not bind GHSR-
1a and does not activate the GH/IGF-1 axis, counteracted muscle 
atrophy induced by either fasting or denervation. Consistently, 
UnAG has been reported to reduce burn-induced skeletal muscle 
proteolysis and local TNF-α upregulation (51).
We achieved upregulation of circulating UnAG either by myocar-
dial Ghrl overexpression in Myh6/Ghrl mice or by repeated admin-
istration. The antiatrophic activity of UnAG cannot be mediated 
by its conversion to AG in the plasma, since acylation occurs only 
intracellularly on the ghrelin precursor by the ghrelin-specific acyl-
transferase GOAT (11, 12). The negligible myocardial expression 
of GOAT might explain the increase of only the unacylated form 
Figure 3
Myh6/Ghrl mice are protected from skeletal muscle atrophy induced by 48 hours of fasting. (A–C) 
Effect of fasting on gastrocnemii. Mean percentage of gastrocnemius weight loss (A) and CSA reduc-
tion (B) of fasted Myh6/Ghrl (Tg) mice and WT littermates compared with fed animals. (C) Frequency 
distribution of gastrocnemii CSA of fasted Myh6/Ghrl and WT mice. (D–F) Effect of fasting on EDL 
muscles. Mean percentage of EDL muscle weight loss (D), CSA reduction (E), and CSA frequency 
distribution (F) of fasted Myh6/Ghrl and WT littermates. (G and H) Atrogin-1 and MuRF1 expression 
in gastrocnemii of fed and fasted Myh6/Ghrl mice and their WT littermates, determined by real-time 
RT-PCR. *P < 0.01 vs. WT. n = 7 (fed WT and Myh6/Ghrl); 5 (fasted WT); 6 (fasted Myh6/Ghrl); 3 (CSA 
loss and distribution, WT and Myh6/Ghrl).
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of circulating ghrelin in Myh6/Ghrl mice. This is in agreement with 
other tissue-specific Ghrl Tg mice featuring high UnAG circulating 
levels in the absence of significant changes of AG (43–45).
The observations that Myh6/Ghrl mice did not feature any 
change in circulating and muscular IGF-1 or in tibial or whole 
body length, along with the lack of skeletal muscle hypertrophy, 
further indicate that the GH/IGF-1 axis is not activated in these 
mice. Finally, the finding that both AG and UnAG impaired skele-
tal muscle atrophy in Ghsr–/– mice indicated that their antiatrophic 
activity is mediated by a receptor distinct from GHSR-1a. In these 
mice, AG exerted antiatrophic activity in the skeletal muscle inde-
pendent of its role in modulating GH release and energy balance. 
Nevertheless, these data do not exclude the possibility that in WT 
animals, GHSR-1a may contribute to the antiatrophic activity of 
AG by also regulating the GH/IGF-1 axis and positive energy bal-
ance. For instance, AG has been suggested to prevent downregu-
lation of muscular IGF-1 expression in an experimental model 
of cachexia through an indirect mechanism involving GHSR-1a 
activity on positive energy balance (20).
The hypothesis that AG/UnAG impairs muscle atrophy in vivo 
by acting directly on the skeletal muscle is further supported by 
our finding that UnAG administration rapidly stimulated anti-
atrophic signaling in the gastrocnemius. Moreover, AG/UnAG 
activated antiatrophic signaling in cultures of C2C12 myotubes, 
which do not express GHSR-1a, protecting them from dexameth-
asone-induced atrophy and atrogene upregulation. Although AG 
has previously been reported to fail in reducing dexamethasone-
induced Atrogin-1 expression in C2C12 myotubes (20), the 10-fold 
lower dexamethasone concentration used in that study and the 
considerably weaker Atrogin-1 induction may explain the differ-
ent results. Conversely, Sheriff et al. showed that UnAG reduces 
TNF-α/IFN-γ–induced cachexia in C2C12 myotubes in a PI3K/
mTOR-dependent manner (51). The results of our present study 
not only confirmed the involvement of PI3K/mTOR pathways in 
AG/UnAG activity on skeletal muscle, but also showed the spe-
cific contribution of the mTORC2- over the mTORC1-mediated 
signaling pathway, which may explain, at least in part, the ability 
of AG/UnAG to protect from skeletal muscle atrophy without a 
concomitant induction of hypertrophy.
Indeed, the molecular mechanisms underlying AG/UnAG antia-
trophic activity in the skeletal muscle involved the activation of 
mTORC2-mediated signaling pathways, leading to phosphoryla-
tion of AktS473 and of its substrate FoxO3aT32, which eventually 
impaired Atrogin-1 expression and muscle protein degradation. At 
Figure 4
Myh6/Ghrl mice are protected from denervation-induced skeletal muscle atrophy induced by sciatic nerve resection. (A and B) Mean percent-
age of weight loss (A) and CSA reduction (B) of denervated gastrocnemius at 7 and 14 days after denervation, compared with the unperturbed 
side. (C and D) Frequency distribution of gastrocnemii CSA at 7 and 14 days after denervation in Myh6/Ghrl and WT mice. (E–H) CSA reduction 
and fiber area distribution of (E and F) EDL and (G and H) TA muscles at 7 days after denervation. (I and J) Atrogin-1 and MuRF1 expression, 
determined by real-time RT-PCR, in denervated gastrocnemii at 7 days after denervation, compared with the unperturbed side. **P < 0.01, 
*P < 0.05 vs. WT. n = 6 (WT); 5 (Myh6/Ghrl); 3 (CSA loss and distribution, WT and Myh6/Ghrl).
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the same time, in C2C12 myotubes, AG/UnAG failed to stimulate 
mTORC1-mediated phosphorylation of S6KT389 and S6S235/236, pro-
tein synthesis, and hypertrophy. Consistently, chronic upregulation 
of circulating UnAG in Myh6/Ghrl mice did not induce muscle 
hypertrophy. This finding highlights a remarkable difference 
between the antiatrophic activities of AG/UnAG and IGF-1 in 
the skeletal muscle, as IGF-1 stimulates both mTORC2-mediat-
ed impairment of protein degradation and mTORC1-dependent 
stimulation of protein synthesis and hypertrophy (23–26). Consis-
tently, in TNF-α/IFN-γ–treated C2C12 myotubes, UnAG inhibited 
protein catabolism and impaired the induction of Atrogin-1 and 
MuRF1. Moreover, UnAG restored the basal phosphorylation state 
of proteins of mTORC1 and mTORC2 pathways, although the lack 
of UnAG-induced increase in AktS473 phosphorylation observed 
herein may depend on receptor desensitization, given the higher 
concentration of UnAG used and the protracted treatment (51).
The finding that downregulation of the mTORC1-specific 
component raptor did not affect the antiatrophic activity of AG/
UnAG, while impairing IGF-1 antiatrophic activity, further sup-
ports the conclusion that AG/UnAG antiatrophic activity does not 
involve mTORC1-mediated stimulation of protein synthesis. On 
the other hand, the finding that AG/UnAG antiatrophic activity 
was sensitive to downregulation of rictor, the specific component 
of mTORC2, demonstrated the key role of mTORC2 in mediating 
AG/UnAG antiatrophic activity. The finding that ghrelin-induced 
phosphorylation of AktS473 was uncoupled from the activation of 
mTORC1-mediated pathways and hypertrophy may appear con-
troversial, as IGF-1–induced phosphorylation of AktS473 is associ-
ated with the activity of both mTOR complexes (29), and overex-
pression of constitutive active Akt in the skeletal muscle prevents 
denervation-induced atrophy and induces hypertrophy (22, 52). 
The lack of muscle hypertrophy observed in Myh6/Ghrl mice may 
depend on weaker stimulation of the PI3K/Akt pathway by UnAG. 
Indeed, although tissue-specific expression of constitutive active 
Akt in Tg mice induces strong phosphorylation of Akt and of 
its substrates (53), phosphorylation of Akt was not detectable in 
Figure 5
UnAG pharmacological treatment protects skeletal muscle from fasting- and denervation-induced atrophy in WT mice. (A–C) Phosphorylation of 
AktS473, FoxO3aT32, and p38T180/Y182 in gastrocnemii of WT mice treated with 100 μg/kg UnAG or saline. At the indicated time points, gastrocnemii 
were removed and processed for Western blot analysis. Shown are representative blots and densitometric analysis of 3 independent experi-
ments, normalized to untreated animals (not shown). (D–F) Mean percent weight loss (D), CSA reduction (E), and CSA frequency distribution 
(F) of gastrocnemii from fed or 48-hour fasted mice treated twice daily with 100 μg/kg UnAG or saline (n = 5 per group). Frequency distribution 
was measured in 3 mice per group. In D and E, percent reduction shown is between fasted and fed mice. (G–I) Mean percent weight loss (G), 
CSA reduction (H), and CSA frequency distribution (I) of gastrocnemii from mice treated with 100 μg/kg UnAG or saline twice daily for 7 days 
after sciatic nerve resection (n = 5 per group). Frequency distribution was measured in 3 mice per group. In G and H, percent reduction shown is 
between denervated gastrocnemii and gastrocnemii from the unperturbed side. *P < 0.05, **P < 0.01 vs. saline treatment.
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muscles of Myh6/Ghrl mice (data not shown). Indeed, we found 
that 2 distinct PI3K isoforms, namely PI3Kβ and PI3Kα, mediated 
the antiatrophic activity of AG/UnAG and IGF-1, respectively. This 
observation, along with the ability of a Gαs-uncoupling drug to 
abolish the antiatrophic activity of AG/UnAG, but not IGF-1, is 
consistent with the hypothesis that the unknown receptor mediat-
ing the common activities of AG/UnAG is a GPCR (9). Moreover, 
these data further serve to rule out the hypothesis that AG/UnAG 
acts on myotubes by stimulating the autocrine release of IGF-1.
The inability of AG and UnAG to stimulate protein synthesis and 
hypertrophy in the skeletal muscle is consistent with their key role 
in the adaptive response to fasting and negative energy balance 
(13). The molecular mechanisms underlying the uncoupling of 
mTORC2 from mTORC1 remain to be investigated. AG and UnAG, 
which are released during fasting, might shift muscle metabolism 
toward amino acid oxidation, thereby decreasing the intracellular 
pool of free amino acids essential for mTORC1 activity (29). Alter-
natively, activation of PI3Kβ, whose enzymatic activity is lower than 
that of PI3Kα (54), may result in weaker activation of Akt. Finally, 
AMPK, which negatively regulates mTORC1 in skeletal muscle 
(55), may contribute to mTORC1 uncoupling, although AG was 
reported to be unable to stimulate AMPK in rat gastrocnemius (56).
The finding that p38 was required for AG/UnAG antiatrophic 
activity is consistent with previous findings that p38 cooperates 
with PI3K/Akt pathways to induce C2C12 differentiation (16, 57). 
However, the role of p38 in regulating muscle atrophy is complex, as 
its activation mediates muscle atrophy induced by oxidative stress 
and inflammatory cytokines (34, 36, 58). The role of p38 in signal-
ing is determined by its association in distinct signaling complexes 
with different regulators and substrates and by its localization 
(35). Our findings are consistent with evidence indicating that, in 
myotubes, decreased p38 phosphorylation is associated with dexa-
methasone-induced atrophy, and that p38 mediates β-hydroxyl- 
β-methylbutyrate protection from dexamethasone-induced protein 
degradation (59, 60). Moreover, p38 activity can regulate cytoplas-
mic localization of FoxO3a independently of Akt, thereby impairing 
its transcriptional activity and Atrogin-1 induction (33, 61). Fur-
thermore, activation of p38 stabilizes and activates the transcrip-
tional coactivator PGC1α, which represses FoxO3a activity (62, 
63). Although IGF-1 activated p38, this was dispensable for IGF-1 
antiatrophic activity. In addition, IGF-1 and AG/UnAG antiatrophic 
activities differed in the inability of AG/UnAG to downregulate 
myostatin, a TGF-β–like inhibitor of muscle growth, which further 
supports the hypothesis that AG/UnAG and IGF-1 counteract mus-
cle atrophy through distinct molecular mechanisms.
The data presented herein unveiled a novel component of the 
complex role of AG/UnAG, i.e., the direct activation of antia-
trophic pathways in the skeletal muscle, eventually leading to 
reduced muscle wasting. This effect adds to the well-known capa-
bilities of AG to stimulate appetite, regulate lipid metabolism, and 
release GH. Although the identity of the novel AG/UnAG receptor 
is yet unknown, these findings may have important biological and 
therapeutic implications, since they provide proof that UnAG has 
a strong and specific potential for the prevention or treatment of 
muscle atrophy, avoiding the diabetogenic side effects of AG (47) 
and the cancer risk associated with IGF-1 treatment (64).
Methods
Reagents. AG1–28 and UnAG1–28 were purchased from PolyPeptide Laborato-
ries. The PI3K p110α inhibitor PIK-75 hydrochloride was purchased from 
Axon Medchem, and the PI3K p110β inhibitor TGX-221 was a gift from 
U. Galli (Synthetic Medicinal Chemistry group, Università del Piemonte 
Orientale, Novara, Italy). Water-soluble dexamethasone and all other 
reagents, unless otherwise stated, were from Sigma-Aldrich. Anti–phos-
pho-AktS473, anti-Akt, anti–phospho-FoxO3aT32, anti-FoxO3a, anti–phos-
pho-S6KT389, anti-S6K, anti–phospho-S6S235/236, anti-S6, anti-p38T180/Y182, 
anti-p38, anti-raptor, and anti-rictor antibodies were from Cell Signaling 
Technology; anti-actin antibody was from Santa Cruz Biotechnology.
Cell cultures and myotube analysis. C2C12 myoblasts were differentiated in 
myotubes as previously described (16). For measurement of myotube diam-
Figure 6
AG and UnAG pharmacological treatment of 
Ghsr–/– mice induces antiatrophic signaling and 
protects from fasting-induced skeletal muscle 
atrophy. (A) Phosphorylation of AktS473 in gas-
trocnemii of Ghsr–/– mice injected with 100 μg/
kg AG or UnAG or with saline. 60 minutes after 
treatment, gastrocnemii were removed and pro-
cessed for Western blot analysis. Shown are 
representative blots and densitometric analysis 
of 3 independent experiments. (B–D) Mean per-
centage weight loss (B), CSA reduction (C), and 
CSA frequency distribution (D) of gastrocnemii 
from fed or 48-hour fasted Ghsr–/– mice injected 
s.c. twice daily with 100 μg/kg AG or UnAG or 
with saline (n = 5 per group). Frequency distribu-
tion was measured in 3 mice per group. In B and 
C, percent reduction is between fasted and fed 
mice. *P < 0.05, **P < 0.01 vs. saline treatment.
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blood glucose meter (Roche Diagnostics). For insulin sensitivity determina-
tion, Humulin R (0.75 U/kg body weight; Lilly) was administered i.p., and 
blood samples for glucose concentrations were collected as described above.
RNA extraction and analysis. Total RNA from cultured myotubes and from 
muscles was extracted by TRIreagent (Invitrogen). The RNA was retro-tran-
scribed with High-Capacity cDNA Reverse Transcription Kit (Invitrogen), 
and real-time PCR was performed with the ABI7200 Sequence Detection 
System (Invitrogen) using the following assays: Mm00499518_m1 (Fbxo32, 
Atrogin-1), Mm01185221_m1 (Trim63, MuRF1), Mm00439560_m1 (Igf1), 
Mm00445450_m1 (Ghrl), Mm01254559_m1 (Mstn), Mm01247058_m1 
(Pck1), Mm00446953_m1 (Gusb), and Mm00506384_m1 (Ppif).
Muscle sampling and staining for fiber size assessment. Muscles were embed-
ded in Killik compound (Bio-optica) and frozen in liquid nitrogen–cooled 
isopentane. Serial transverse cryosections (7 μm thick) of the midbelly 
region of muscles were cut at –20°C and mounted on glass slides. The 
sections were air-dried, fixed for 10 minutes in 4% paraformaldehyde, and 
stained with H&E. The number of myofibers in TA, gastrocnemii, and EDL 
was measured from the histological preparations. Muscle fiber CSA was 
assessed as previously described (67). Data are expressed as fiber size dis-
tribution and as percent CSA reduction relative to controls.
Grip strength test. Skeletal muscle force was assessed using the BS-GRIP 
Grip Meter (2Biological Instruments) as previously described (68). Each 
animal was tested 3 times, and the average value of the maximum weight 
that the animal managed to hold was recorded and normalized to the 
mouse’s weight.
Statistics. Data are presented as mean ± SEM. Variation among groups 
was evaluated using nonparametric Wilcoxon and Mann-Whitney U tests. 
Statistical significance was assumed for P values less than 0.05. All statisti-
cal analyses were performed with SPSS for Windows version 17.0.
Study approval. All animal experimental procedures were approved by the 
Institutional Animal Care and Use Committee at Università del Piemonte 
Orientale “Amedeo Avogadro.”
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eters, myotubes were fixed, and diameters were quantified by measuring a 
total of >100 myotube diameters from 5 random fields in 3 replicates at 
×40 magnification using Image-Pro Plus software (MediaCybernetics) as 
described previously (24).
Raptor and rictor silencing. Raptor siRNA (MISSION pre-designed siRNA SASI_
Mm01_00055293; Sigma-Aldrich), rictor siRNA (SASI_Mm01_00137731; 
Sigma-Aldrich), Block-iT, or siRNA negative control sequence (Invitrogen) 
were transfected with Lipofectamine2000 (Invitrogen) in C2C12 myotubes. 
Transfection efficiency was evaluated by the fluorescent siRNA negative 
control Block-iT, and silencing was verified by Western blot.
[3H]-leucine incorporation assay. C2C12 myotubes were maintained for 
24 hours with or without 10 nM AG or UnAG in differentiation medium 
supplemented with 2 μCi/ml [3H]-leucine (Perkin Elmer) to evaluate the 
induction of protein synthesis. At the end of treatments, cells were washed 
with PBS, treated with 5% trichloroacetic acid, and lysed with 0.5 M 
NaOH and 0.5% SDS. The amount of incorporated [3H]-leucine was evalu-
ated by β counter (Tri-Carb 2800TR; Perkin Elmer) analysis. Data are the 
average of 4 replicates.
Western blot. C2C12 myotubes were serum starved overnight and then 
treated as indicated in the figure legends. Western blot was performed as pre-
viously described (16). Unless otherwise specified, after use of anti–phospho-
specific antibodies, membranes were stripped with Re-Blot Plus (Chemicon, 
Millipore) and reblotted with the corresponding total protein antibodies.
Muscles of mice fasted for 6 hours were s.c. injected with 100 μg/kg 
UnAG or AG or with saline solution. At the indicated time points, gas-
trocnemii were removed, homogenized at 4°C in RIPA buffer (1% Triton 
X-100; 1% sodium deoxycholate; 0.1% SDS; 1 mM EDTA; 1 mM EGTA; 
50 mM NaF; 160 mM NaCl; and 20 mM Tris-HCl, pH 7.4) containing 
1 mM DTT, protease inhibitor cocktail, and 1 mM Na3VO4. Homogenates 
were then processed as above.
Tg animal generation and treatment. All experiments were conducted on 
young adult male FVB1 WT, FVB1 Myh6/Ghrl, and C57BL/6J Ghsr–/– mice 
(50), matched for age and weight.
Tg animals were obtained by cloning the murine ghrelin gene (Ghrl) 
under control of the cardiac promoter sequences of the β myosin heavy 
chain 3′ UTR and the first 3 exons of the α isoform Myh6 (65). Transgene 
integration and expression were confirmed by PCR and real-time RT-PCR, 
respectively. Phenotypical characterization and experiments were carried 
out on hemizygote animals and littermate controls.
AG, UnAG, and IGF-1 plasmatic levels were measured by EIA kits (SPIbio 
Bertin Pharma for AG and UnAG; R&D Systems for IGF-1); insulin plas-
matic levels were quantified with the Insulin (mouse) ELISA kit (ALPCO 
Diagnostics); and glycerol and free fatty acid plasmatic levels were evalu-
ated by enzymatic assay kits (Cayman).
BMI was calculated as animal weight divided by the square of the 
nasoanal length.
Fasting-induced atrophy was achieved by 48 hours of food removal (63), 
while denervation-induced muscle atrophy was obtained by resection of 
the sciatic nerve under anesthesia with sevoflurane (Baxter) and evaluated 
7 and 14 days later (66). Muscles were collected, weighed, and normalized 
for tibial length and processed either for RNA extraction or for histology.
Daily food intake was measured over a 12-day period, quantifying the 
food consumption of each mouse every day.
In all experiments with s.c. injection of AG and/or UnAG, controls were 
saline-injected animals.
Glucose and insulin tolerance tests. Glucose tolerance and insulin sensitivity 
tests were performed as previously described (43). For glucose tolerance 
evaluation, mice were injected i.p. with glucose at 1.5 mg/g body weight 
at 9:00 am, after 16 hours of fasting. Blood glucose was determined at the 
indicated time points on tail blood samples using the Accu-Chek Mobile 
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Figure S1. 
Long rapamycin treatment impairs both mTORC1 and mTORC2 activities in C2C12 myotubes. (A-B) 
Phosphorylation of S6KT389 and AktS473 detected by western blotting upon treatment for 20 min with 1 mM 
AG or UnAG. Upper panels: representative blots; lower panels: quantifications of 3 independent 
experiments. Rapamycin (RAP) 20 ng/ml was used for 1 h or 24 h. After short rapamycin treatment (1 h), 
mTORC1-mediated phosphorylation of S6KT389 is completely abolished (A), while the activity of mTORC2-
mediated phosphorylation of AktS473 is spared (B). On the other hand, upon 24 h of rapamycin treatment, 
AktS473 phosphorylation is also abrogated, indicating that long rapamycin treatments affect mTORC2 activity 
as well as mTORC1 in C2C12 myotubes. #P < 0.05 versus control cells in DM. 
(C) AG and UnAG do not affect dexamethasone (DEXA)-induced myostatin expression, measured by real-
time RT-PCR. C2C12 myotubes were treated in DM for 24 h with 1 mM DEXA in the presence or absence of 
10 nM AG or UnAG, or 10 ng/ml IGF-1 and processed for myostatin expression analysis. §P < 0.01 versus 
control cells in DM; *P < 0.01 versus DEXA-treated cells. 
Figure S2.  
(A) Ghrelin expression is specifically induced in the hearts of Myh6/Ghrl mice without any leaky 
expression in skeletal muscle. The expression in the stomach, the main source of AG and UnAG, is not 
altered in Myh6/Ghrl animals. §P < 0.01 versus WT mice. (B) IGF-1 expression in skeletal muscle is not 
altered in Myh6/Ghrl mice, either fed or starved animals (fed WT and Tg, n = 5; starved WT, n = 5; staved 
Tg, n = 6). (C and D) Myh6/Ghrl mice do not feature significant differences in glucose uptake (C) and 
insulin resistance (D) compared to WT littermates. For the glucose tolerance test, mice were injected after 
16 h of fasting (WT and Tg, n = 5). (E and F) Myh6/Ghrl mice do not feature significant differences in 
muscle-fiber distribution and force compared to WT littermates. (E) Gastrocnemii were removed from fed 
animals and mean fiber CSA and distribution were analyzed (WT and Tg, n = 3). Mean gastrocnemius CSA 
of fed animals  SEM (mm2) WT: 2,165.65  290.85; Tg: 1,871.15  100.86. (F) The weight that WT and 
Tg animals managed to hold up before losing grip was measured through a Grip Meter device and 
normalized to the weight of animals (WT and Tg, n = 5). (G-I) Myh6/Ghrl mice do not feature significant 
differences in plasmatic glycerol (G) and FFA (H), nor in liver PEPCK expression (I) compared to WT 
animals, in either fed or starved animals (n = 5 for each group).  
Figure S3.  
(A) UnAG plasma concentration upon UnAG treatment. WT mice (n = 2) were injected s.c. with 100 
μg/kg UnAG and, at the indicated time points, blood samples were collected by retro-orbital puncture and 
processed for EIA determination of plasmatic UnAG concentration. Each sample was loaded in triplicates 
and mean values ± SD are represented. (B) IGF-1 expression in skeletal muscle is not altered after UnAG 
injection compared to saline treatment (n = 5 for each group). 
